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ABSTRACT 
Background: Antiphospholipid antibodies (aPL) are associated with a heterogeneous range of clinical conditions with 
predisposition for thrombosis, pregnancy morbidity and other autoimmune disorders, most frequently systemic lupus 
erythematosus (SLE). Both the clinical manifestations themselves and their treatment may be harmful to the affected 
individuals and aPL testing is still controversial. There is thus an urgent need for improved aPL diagnostics and 
individual risk assessments. Exploring the largely unknown disease aetiology may provide clues to new biomarkers. 
From previous studies of other pro-thrombotic conditions, we hypothesized that fibrin clot properties, fibrinolytic 
function, microparticle (MP) profile and smoking could be important in aPL-related disease. 
Aims: To study clinical, serological and haemostatic features of the antiphospholipid syndrome (APS) and aPL-related 
disorders, including SLE, in order to improve diagnostic methods and enhance understanding of disease pathogenesis.  
Materials and methods: Two patient groups were cross-sectionally studied. In paper I, IV, and V, the Karolinska SLE 
cohort was studied; in paper I together with patients from the Swedish SLE network (n=712 patients) and in paper IV in 
comparison with matched population controls (n=290 patients). In paper II and III, APS patients (n=49 and 52 patients, 
respectively) from Karolinska University Hospital were compared both to healthy controls (paper II and III) and to non-
APS thrombotic controls (paper II).  Laboratory assays included: different ELISAs for aPL detection, liquid permeation 
technique and scanning electron microscopy (SEM) for examination of fibrin network permeability and structure, 
turbidimetric clotting and lysis assays, and finally MP measurement by flow cytometry. 
Results: In paper I, we report only moderate agreement (Kappa-values 0.16-0.71) but similar, modest association with 
previous thrombotic events when comparing a new automated aPL method with standard assays in SLE patients. Antibody 
isotype and titer influenced the association with clinical events. Odds ratios for lupus anticoagulant (LA) for the 
associations with vascular events were generally higher than for the specific aPL immunoassays. In paper II, we report 
that fibrin clots formed in vitro in samples from APS patients have a decreased permeability compared to the clots formed 
in samples from healthy controls and non-APS thrombosis controls (p<0.0001 for both). SEM images visually confirmed 
denser fibrin structure in APS. No clear difference in fibrinolysis function between the APS patients and controls were 
observed (p>0.05 for two of the three investigated parameters) but APS patients with previous arterial thrombosis had 
prolonged clot lysis times compared to the controls (p<0.05). In paper III, we report that the number of lactadherin 
positive MPs, endothelial MPs, Tissue factor (TF)-positive endothelial MPs and monocyte MPs in APS samples were 
increased compared to healthy controls (p<0.001 for all analyses). There was no significant difference in the number of 
platelet MPs (p=0.13). APS patients had a high proportion of MPs negative to lactadherin. In paper IV, we report that the 
number of lactadherin positive MPs, endothelial MPs, platelet MPs and leukocyte MPs  in SLE samples were increased 
compared to matched population controls (p<0.0001 for all analyses). Moreover, MPs exposing inflammation and/or 
activation markers such as CD40L, TF, vascular cell adhesion molecule 1(VCAM-1), high-mobility group protein B1 
(HMGB1) and C4d also were also clearly increased in the SLE patients (p<0.0001 for all analyses). However, MP number 
could neither be used to distinctively discriminate between SLE patients with or without APS nor between SLE patients 
with or without previous vascular events in multivariable models (p-values for all analyses >0.05 except for VCAM-1-
positive endothelial MPs which had p-values of 0.044 and 0.047 for positive associations in the vascular event models). In 
paper V we report a positive association between cigarette smoking (ever smoking and, most strikingly, former smoking) 
and the presence of aPL among patients with SLE (OR ≈3 for aPL of the IgG isotype and for LA and former smoking vs. 
never smoking in a multivariable model). A positive interaction between ever smoking and aPL was noted for the 
association with previous vascular events. The additive interaction analysis demonstrated a significant interaction between 
ever smoking and LA (attributable proportion due to interaction, AP=0.80, 95% CI 0.5 - 1.0) and ever smoking and triple 
aPL positivity (AP=0.85, 95% CI 0.6 - 1.0) for the association with presence of previous vascular events. 
Conclusions: Automated aPL assays are promising for facilitating aPL testing. However, it is crucial to also evaluate LA 
positivity, antibody titers and isotypes together with smoking status when aPL results are used for risk assessment in 
individual patients. Smoking, abnormal fibrin clot properties, fibrinolytic function, and MP profile may contribute to the 
pathogenesis of aPL-associated disease. MP formation is likely to play a role in SLE as well, which is a disorder closely 
related to APS. However, the exact relationship between aPL, vascular events and MPs in SLE patients needs to be further 
studied. Further mechanistic studies are needed to address how the different variables studied in this thesis are related to 
the pathogenesis of aPL-associated disease. The findings and conclusions in this thesis also need to be prospectively 
studied to clarify their prognostic value. With such additional studies, our observations could guide the search for new 
biomarkers and risk scores in aPL-related disease. 
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LIST OF ABBREVIATIONS  
 
AAE Any arterial event 
aAnAV Anti-annexin V 
aCL Anticardiolipin 
ACR American College of Rheumatology 
AM Automated method 
ANA Antinuclear antibody 
Anti-dsDNA Anti-double-stranded DNA 
Anti-Sm Anti-Smith 
anti-β2GPI Anti-β2 glycoprotein-I 
APC Activated protein C 
aPL Antiphospholipid antibodies 
APS Antiphospholipid syndrome 
APTT Activated partial thromboplastin time 
ASA Acetylsalisylic acid 
AVE Any vascular event 
CAPS Catastrophic antiphospholipid syndrome 
CVD Cardiovascular disease 
dRVVT dilute Russell’s viper venom time 
DVT Deep venous thrombosis 
E-selectin Endothelial Selectin 
ELISA Enzyme-linked immunosorbent assay 
EMPs Endothelial microparticles 
eNOS Endothelial nitric oxide synthase 
ErMPs Erytrocyte microparticles 
HCs Healthy controls 
HMGB1 High-mobility group protein B1  
hsCRP High-sensitivity C-reactive protein 
ICAM-1 Intercellular adhesion molecule 1 
  
ICVD Ischemic cerebrovascular disease 
IHD Ischemic heart disease 
INR International normalized ratio 
IPVD Ischemic peripheral vascular disease  
LA Lupus anticoagulant 
LE cell  Lupus erythematosus cell 
LMPs Leukocyte microparticles 
LR Livedo reticularis 
MI Myocardial infarction 
MMPs Monocyte microparticles 
MPL/GPL IgM/IgG phospholipid units 
MPs Microparticles 
mTORC Mammalian target of rapamycin complex 
Non-APS TCs Non-APS thrombotic controls 
NSAID Non-steroidal anti-inflammatory drug 
OR odds ratio 
PAI-1 Plasminogen activator inhibitor-1 
PE  Pulmonary embolism 
PMPs Platelet microparticles 
PS Phosphatidylserine 
PT Prothrombin 
RF Reumatoid factor 
RFL Recurrent fetal loss 
RM Routine method 
SEM Scanning electron microscopy 
SLE Systemic lupus erythematosus 
SVT Superficial vein thrombosis 
TAFI Thrombin-activatable fibrinolysis inhibitor  
TEM Transmission electron microscopy  
TF Tissue Factor 
TIA Transient ischemic attack 
   
tPA Tissue plasminogen activator 
VCAM-1 Vascular cell adhesion molecule 1 
VLDR Venereal Disease Research Laboratory 
VTE Venous thromboembolism 
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1 BACKGROUND: WHY ARE STUDIES OF ANTIPHOSPHOLIPID 
ANTIBODIES (APLS) AND ANTIPHOSPHOLIPID SYNDROME (APS) 
URGENT?  
 
1.1 APS is a relatively “new” disease with recently updated criteria 
The antiphospholipid syndrome (APS), first described in the 1980s (1, 2), is characterized by 
thrombosis or obstetric morbidity (clinical criteria) in conjunction with the presence of 
antiphospholipid antibodies (aPL) (laboratory criteria). At least one clinical and one laboratory 
criterion are required for APS classification (see Figure 1). Thrombotic manifestations can 
affect any vessel including the arterial, venous or microvascular circulation. Obstetric morbidity 
includes miscarriages, premature birth, and foetal death. The laboratory criterion is fulfilled 
through persistent positivity (minimum of two positive tests taken at least 12 weeks apart) for 
either antibodies against cardiolipin of IgG or IgM isotype (IgG aCL, IgM aCL) or antibodies 
against the phospholipid binding cofactor β2glycoprotein-I of IgG or IgM isotype (IgG anti-
β2GPI, IgM anti-β2GPI ) detected by enzyme-linked immunosorbent assays (ELISA) or the 
functional Lupus anticoagulant (LA) test. At least 12 weeks and no more than 5 years should 
separate the clinical event and the positive test. Furthermore, for study purposes, it is 
recommended that APS patients are subclassified into one of the following categories: I, more 
than one laboratory criteria present; IIa, LA alone present; IIb, aCL alone present; IIc, anti-
β2GPI alone present (3).  
 
Figure 1: Classification criteria for Antiphospholipid syndrome (APS) 
aCL=anticardiolipin. anti-β2GPI= Anti-β2 glycoprotein-I. LA=Lupus anticoagulant. 
12 
It has been argued that while it is important to have a universal definition of APS for study
reasons, this concept might be misleading in the clinical context. According to this view, aPL
testing in clinical practice is perhaps better regarded as part of a general risk stratification for
thrombotic events, pregnancy complications etc. in certain groups of patients, rather than a
diagnostic procedure (4, 5).  
1.2 Knowledge of APS and aPL prevalence is limited 
Data on the prevalence of this condition in the general population is meagre. Using the current 
cut-offs for aPL assays, at least 1% of healthy individuals will, by definition, be positive for
aPL without having any clinical manifestations of APS (3). A recent literature review 
estimated the overall frequency of aPL positivity in different patient populations. They
reported 6% for pregnancy morbidity, 13.5% for stroke, 11% for myocardial infarction (MI),
and 9.5% for deep venous thrombosis (DVT). However, the authors of this review highlighted
the difficulties in extracting such figures from the existing literature due to use of non-criteria 
cut-offs for aPL, non-criteria definitions for events, and heterogeneity in study design (6). 
New studies tend to investigate the subject more according to current APS criteria. Gris et al 
screened 6318 patients under investigation for unexplained pregnancy loss for aPL (anti-
β2GPI, aCL, and LA), and found that 8.2% were persistently positive (7). In a study of 150
young patients (<50 years) with ischaemic stroke, Renna et al diagnosed 12.7% with APS (8). 
In a large case control study called RATIO (Risk of Arterial Thrombosis In relation to Oral 
contraceptives), LA positivity was found in 17% of young women with ischaemic stroke (<50
years old) and in 3% of young women with MI (9). In a study of 443 patients with venous 
thromboembolism utilising the current APS criteria, the percentage of aPL-positive patients 
was surprisingly low: 0.7-3.1%, comparable to the control group. A similar result was 
observed for the proportion of patients with venous thrombosis that were aCL-positive at the 
99th percentile cut-off in a large population-based nested case-cohort study (10). 
APS and aPL are more common in individuals with other autoimmune disorders but the same 
problem as for the general population occurs when estimating the true prevalence. In a review 
from 2010, the prevalence of aPL among patients with systemic lupus erythematosus (SLE)
was 12-44% for aCL, 10-19% for anti-β2GPI, and 15-34% for LA (11). In a group of SLE 
patients from mid-/southern Sweden the prevalence of aPL was 18.8% for IgG aCL, 21.8%
for IgM aCL, 20.3% for anti-β2GPI, and 19.4% for LA (12). In an older retrospective study
where 21 aCL-positive patients with SLE or other connective tissue diseases were followed
for 10 years, 11 patients (52%) developed clinical features of APS (13). In the multicentre 
cohort of 1000 APS patients followed in the Euro-Phospholipid project, 36% had SLE, 5%
had lupus-like syndrome, and 5% had other associated diseases (14). In a retrospective cohort 
study of 80 Brazilian APS patients, 14 patients (17.5%) subsequently developed SLE in an
average time of 5.2+/-4.3 years (15). 
Most APS patients are women; 82% of the patients in the Euro-Phospholipid cohort are 
female (14). 
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1.3 APS is a heterogeneous and potentially severe condition 
The clinical features associated with aPL positivity are diverse. Apart from the established 
APS criteria manifestations, features include heart valve disease, livedo reticularis (LR), skin 
ulcerations, thrombocytopenia, and various neurological manifestations such as cognitive 
dysfunction, migraine, transverse myelopathy, and epilepsy (3). The most severe form of APS 
is known as catastrophic APS (CAPS, Asherson’s syndrome). It is characterized by the 
development of life-threatening multiorgan thrombosis (>2 organs) over a brief period of time 
(<1 week) in association with microthrombosis and persistent aPL positivity (16, 17). 
Current treatment options for APS are long-term oral anticoagulation (for venous and arterial 
thrombosis), heparin (for obstetric APS), and acetylsalicylic acid (ASA, for certain aPL 
carriers, obstetric APS, and some arterial events). For CAPS, the therapeutic arsenal includes 
anticoagulation, steroids, intravenous immunoglobulins, and plasmapheresis/plasma 
exchange. This arsenal may also be used in addition to conventional treatments in high-risk 
APS pregnancies. Drugs such as statins, hydroxychloroquine, B-cell inhibitors, new oral 
anticoagulants (NOACs), older non-heparin/warfarin anticoagulants, complement inhibitors, 
and peptide therapies are being discussed as possible therapeutic options and tested for 
various APS manifestations (18-22).  
Since both the disorder itself and its treatments can potentially harm the affected individual, 
both under- and over-treatment must be avoided. To achieve this, large randomised trials are 
required to estimate treatment effects on a group level. However, there is also a need to 
improve APS diagnostics and to identify better biomarkers to individualise care. 
 
1.4 Laboratory testing for aPL is problematic and better prognostic 
tools/biomarkers are needed 
1.4.1 Controversies exist regarding the strength of association between clinical manifestations 
and positive aPL tests  
Despite the extensive body of literature published over the years on the relationship between 
aPL positivity and APS events, the magnitude of this association is still a matter of debate. In 
two systematic reviews of studies published 1988-2000, Galli et al concluded that a positive LA 
test is a strong risk factor for both arterial and venous thrombosis but that the odds ratios (ORs) 
for aCL and anti-β2GPI tests are not equally convincing. Substantial heterogeneity in study 
design and how the laboratory tests were performed was noted for the included studies and 
further harmonisation of methods was encouraged (23, 24). During the decade that has passed 
since these two reviews were published, the APS criteria have partly changed: anti-β2GPI 
assays have been added, cut-offs for aCL have been defined as >40 IgG/IgM phospholipid units 
(GPL/MPL) or >99th, the interval required between two positive tests increased from six to 
twelve weeks (3) and further studies investigating the relationship between aPL and thrombosis 
have been conducted. To present the findings from all of these studies is beyond the scope of 
this thesis but some of the most prominent publications are cited below and summarised in 
Table 1. The role of aPL in cardiovascular complications in SLE is also further discussed in 
section 1.6. 
Regarding arterial manifestations, a study that prospectively followed individuals referred for 
aPL testing reported that aPL positivity was an independent predictor for new arterial events 
(25). Moreover, the previously cited RATIO study showed that LA was significantly associated 
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with both stroke (OR 43.1) and MI (OR 5.3), while IgG anti-β2GPI was only associated with 
stroke (OR 2.3) and IgG aCL was not associated with either of these two manifestations (9). 
However, in a case-control study of premenopausal women with MI, IgG anti-β2GPI  and IgM 
anti-β2GPI  showed clear associations with the event while the association for IgG aCL was less 
prominent but still statistically significant. IgM aCL showed no association (26). A report from 
the Hopkins Lupus Cohort published in 2010 states that both LA, anti-β2GPI, and aCL were 
associated with stroke but only LA was associated with MI (27). In a study from 2012 of the 
same cohort, LA was an independent predictor of cardiovascular events in a multivariable 
model (28). In our Karolinska SLE cohort and in the LUMINA (LUpus in MInorities: NAture 
vs. Nurture) cohort aPL positivity was an independent predictor of arterial events (29, 30). Gris 
et al demonstrated that during a median follow-up time of approximately 9 years persistently 
aPL-positive women with previous pregnancy loss (purely obstetric APS) had increased rates of 
stroke, DVT, pulmonary embolism (PE), and superficial vein thrombosis (SVT) compared to a 
group of non-thrombophilia patients with previous pregnancy losses. The mean risk rates were 
in general nearly twice as high in the first group. However, among the APS patients, positive 
LA was the only aPL test which convincingly and independently predicted thrombosis, while 
IgM aCL positivity seemed rather to protect against events (7). Moreover, in a study of young 
patients with recent ischaemic stroke/transient ischaemic attack (TIA), aPL positivity (LA 
and/or aCL positivity) was neither a risk factor for recurrent cerebral events nor for other 
thrombotic complications (31). 
Concerning venous thrombosis, there are a number of contemporary and relevant studies 
showing a relationship between aPL positivity and clinical events. Besides the aforementioned 
study by Gris et al (7) there is also the 2010 publication from the Hopkins Lupus Cohort 
reporting a significant association between single positivity for LA, anti-β2GPI, and aCL, 
respectively, and (any) venous thrombosis (27). Moreover, there is a large population-based 
case-control study, the Leiden Thrombophilia Study, where a positive LA in the presence of 
anti-β2GPI or antibodies against prothrombin (PT)  was associated with an increased risk for 
DVT corresponding to a mean OR of 10.1 (32). In line with this study, the WASP (warfarin in 
the antiphospholipid) study confirmed the importance of positivity in several aPL tests reporting 
an almost 5- to 7-fold increased risk of prospective thrombosis and abortion for LA-positive 
patients belonging to the upper tertile of both anti-β2GPI and anti-annexin V (aAnAV) (33). In 
another prospective setting, anti-β2GPI was shown to be an independent predictor of new 
venous thrombosis (25). As stated above, there are also, however, recent and important studies 
that have failed to report a convincing relationship between venous thrombosis and aPL 
positivity and that have investigated the association between clinical events and positivity for 
either aCL or LA (34) or aCL single positivity (10).  
Importantly, the question of aPL positivity and risk of thrombosis in non-lupus patients has 
been addressed in a recent meta-analysis of studies from 1990 to 2010, including some of the 
studies mentioned above. Both LA, anti-β2GPI, and aCL were associated with thrombosis even 
though ORs varied according to the manifestation studied (35). 
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Table 1: Selection of recent studies (2004-2014) investigating the relationship between 
antiphospholipid antibodies (aPL) and thrombosis 
Study Population Study 
design 
aPL 
studied 
APS 
manifestation 
Positive 
association 
aPL and 
manifestations: 
Yes/No 
Main findings 
Toloza 
2004 
SLE-
patients 
(n=546) 
Prospective 
cohort 
aPL, LA Arterial 
events 
Yes aPL<->arterial events 
van 
Goor 
2004 
Patients 
<45 years 
with recent 
TIA/stroke 
(n=128) 
Prospective 
cohort 
LA, aCL Arterial and 
venous 
events 
No No association between 
aPL positivity and recurrent 
cerebral events/other 
thrombotic events 
de 
Groot 
2005 
DVT-
patients 
<70 years 
(n=473) 
vs.controls 
(n=472) 
Case-
control 
anti-
β2GPI, 
LA, 
antibodies 
against PT 
DVT Yes anti-β2GPI and  LA<-
>DVT 
Naess 
2006 
Patients 
with 
venous 
thrombosis 
(n=508) 
vs.controls 
(n=1464) 
Population-
based 
nested case 
control 
study 
aCL Venous 
thrombosis 
No No association between 
aCL and venous thrombosis 
Meroni 
2007 
Women 
<45 years 
with first 
MI (n=172) 
vs.controls  
(n=172) 
Case 
control  
aCL, anti-
β2GPI 
MI Yes IgG anti-β2GPI <->MI, IgG 
aCL<->MI. IgM aCL not 
associated 
Galli 
2007 
Patients 
with 
persistent 
aPL(n=112) 
Prospective 
cohort 
aCL, anti-
β2GPI, 
LA,  
antibodies 
against 
PT, 
aAnAv, 
aPS 
Thrombosis 
and obstetric 
events 
Yes Prominently increased risk 
of thrombosis and abortion 
for LA-positive patients 
belonging to the upper 
tertile of anti-β2GPI and 
aAnAV 
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Table 1 (Continued..) 
aCL=Anticardiolipin. anti-β2GPI=Anti-β2 glycoprotein-I. LA=Lupus anticoagulant. SLE=Systemic lupus erythematosus. TIA=Transient 
ischemic attack. DVT=Deep venous thrombosis. MI=Myocardial infarction. PT=Prothrombin. AnAV=Anti-annexin V. aPS=Anti-
phosphatidylserine. PE=Pulmonary embolism. PCI=Percutaneous coronary intervention. n=number. <->=associated with.  
 
 
Neville 
2009 
Individuals 
referred for 
aPL testing 
and full 
blood count 
respectively 
(n=414) 
 
Prospective 
cohort  
aCL, anti-
β2GPI, LA 
Arterial and 
venous events 
Yes aPL <-> arterial events, anti-
β2GPI <-> venous events 
Urbanus 
2009 
Women<50 
years with 
stroke 
(n=175) or 
MI (n=203) 
vs. controls 
(n=628) 
Population-
based case 
control 
aCL, anti-
β2GPI, 
LA,  
antibodies 
against PT  
Stroke and MI Yes LA<->stroke, MI anti-IgG 
β2GPI <-> stroke. IgG aCL 
and  antibodies against PT 
not associated 
Gustafsson 
2009 
SLE-
patients 
(n=182) 
Prospective 
cohort 
aCL, anti-
β2GPI, LA 
Arterial events Yes aPL<->arterial events 
Petri 2010 SLE 
patients (n 
not 
reported) 
Cohort aCL, anti-
β2GPI, LA 
Arterial and 
venous events 
Yes LA, anti-β2GPI and aCL<-
>stroke, LA <->MI 
Magder 
2012 
SLE-
patients 
(n=1874) 
Cohort LA Cardiovascular 
events (MI, 
stroke, angina, 
PCI, coronary 
bypass, 
claudication) 
Yes LA<->cardiovascular events 
Gris 2012 Women 
with 
previous 
pregnancy 
loss 
(n=1592) 
Prospective 
cohort 
aCL, anti-
β2GPI, LA 
Stroke, DVT, 
PE and 
superficial 
vein 
thrombosis 
Yes aPL <-> Stroke, DVT, PE 
and superficial vein 
thrombosis 
Grifoni 
2012 
DVT-
patients 
(n=443) vs. 
controls 
(n=304) 
Case-
control 
aCL, LA DVT No No difference between cases 
and controls regarding aPL 
positivity 
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Obstetric morbidity was not included in the reviews by Galli et al. For women without 
autoimmune disease, thorough meta-analysis show that LA and aCL are convincingly 
associated with recurrent foetal loss (RFL) (36) and aCL with preeclampsia (37). Moreover, the 
relationship between positive aPL and adverse pregnancy outcome has been corroborated in 
prospective settings (38, 39). For pregnancies complicated by SLE, a recent meta-analysis 
confirms an association between aPL and hypertension as well as premature birth (40) and 
many but not all studies report a clear relationship between aPL and pregnancy loss (41-48).   
1.4.2 aPL testing includes a number of complex procedures 
ELISA tests for aCL and anti-β2GPI should be conducted according to the international 
guidelines from 2012, updated in 2014, which describe important preanalytical, analytical, and 
postanalytical issues to be considered. For example, it is important to use a complex of 
cardiolipin and β2GPI (human) in aCL assays, to properly quantify and report the results, to 
demonstrate acceptable precision (coefficient of variation=CV preferably below 10%, 
maximum 20%), and to evaluate the possible IgM-rheumatoid factor (RF) interference. 
Universal units of measurement for the aCL-tests, GPL for IgG, and MPL for IgM, exist for 
quantification. Traditionally, aCL tests are calibrated using calibrators from Louisville APL 
Diagnostics which can be traced back to the original Harris standards, but there are also 
monoclonal calibrators. The cut-off for positivity is set at 40 GPL/MPL or the 99th percentile of 
normal controls. For anti-β2GPI, no universal measurement units exist, so the results are 
reported in arbitrary units. The cut-off for positivity is set at the 99th percentile of healthy 
controls (49, 50). 
The functional LA test is based on indirect evidence of the presence of LA acting on 
phospholipid-dependent clotting tests; quenching the phospholipids required for coagulation so 
that clotting time is prolonged. The test is traditionally performed in three steps: screening, 
mixing, and confirmation. In the screening test, LA is suspected if the clotting time is 
prolonged. In the mixing test, positive plasma from the screening step is retested using the same 
procedure as in the previous step but this time with the addition of normal plasma in a 1:1 ratio 
with patient plasma. If clotting time is still prolonged (and not corrected as would be the case if 
the prolonged clotting time was due to naturally occurring or induced coagulation deficiencies) 
LA is still suspected. In the confirmation test, LA is verified if the prolonged clotting time is 
normalised after addition of increasing amounts of phospholipids and thus identifying the 
inhibitor of coagulation as phospholipid-dependent. As described in the current international 
guidelines published 2009, two different tests based on different principles should be used for 
screening; preferably dilute Russell’s viper venom time (dRVVT), where coagulation is 
activated by a viper venom, and a sensitive activated partial thromboplastin time (APTT) test 
using silica as an activator and low phospholipid concentration. The screening test is positive if 
the clotting time is longer than the local cut-off, preferably set at the 99th percentile of healthy 
blood donors. The mixing test is positive if clotting time is longer than the local cut-off and the 
confirmation test is positive if the clotting time is shorter than the local cut-off value. LA is 
considered present if at least one complete testing procedure is positive (performed with either 
dRVVT or APPT). Problems with LA detection include: loss of low-titer LA if platelets are not 
completely removed before freezing and thawing, interpretation during ongoing antithrombotic 
treatment/acute thrombotic event/presence of coagulation factor inhibitors, as well as generally 
low specificity. For heparins, the recommendation is to postpone testing until treatment is 
discontinued, if possible, but many low molecular weight heparins do not in fact affect the 
testing. For oral anticoagulants, there are different procedures to overcome the effect of the drug 
(like dilution with normal plasma in case of vitamin K antagonists and international normalized 
ratio; INR, 1.5-3), but the results are recommended to be interpreted with caution and ideally, 
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LA testing should be postponed until treatment is stopped or INR<1.5. Detection of LA in 
plasmas containing the new direct oral anticoagulants is not possible with regular assays (51, 
52) (53). The correlation between clinical events and a positive LA can be affected by which 
aPL that is responsible for the observed prolongation of clotting time in vitro (54). 
1.4.3 Assays need to be more standardised 
An important explanation for the conflicting results in the clinical studies of APS is the 
continuing lack of standardisation of how aPL assays are conducted. Consequently, there is 
significant interlaboratory variation (3, 55, 56).  
For LA, the lack of an available “golden standard” laboratory test and the high rate of both 
false-negative and false-positive detections are major issues. Most laboratories can correctly 
identify clearly positive and clearly negative samples, but problems arise when LA is weak. 
There may also be a risk of falsely classifying a very strongly positive sample as negative if the 
mixing test is not used (57). There is an on-going debate concerning the need to routinely 
perform the mixing test. Some argue that current guidelines should be changed and dilution 
with normal plasma only used under some special circumstances (58). 
For ELISA tests for aCL and anti-β2GPI, the lack of reference material and uniform units of 
measurement are important problems. It has been suggested that many problems stemming from 
lack of standardisation could be eliminated if a new common, international primary standard is 
established. The use of monoclonal antibodies has been proposed. Until this goal is reached, 
efforts should be made to improve the existing methods and to standardise cut-offs, procedures 
and materials (53, 59, 60). 
1.4.4 Cut-offs are crucial and have been much discussed 
Over the years many studies, including prospective such, have shown that higher levels of 
aPL are more strongly associated with clinical events than lower levels (61-68). This was also 
the conclusion drawn for aCL when studies on thrombosis were summarised in the systematic 
reviews by Galli et al, although for anti-β2GPI, it was stated that lack of reference material for 
quantification made this type of assessments impossible (23, 24). Moreover, titer affects the 
probability of being positive in more than one aPL test (68). However, it is important but 
difficult to establish the exact threshold that confers a clinically (and not only statistically) 
significant increased risk for events. Moreover, this threshold could vary depending on the 
clinical manifestation studied (68). The current cut-offs for positivity are based on the best 
available evidence in 2006 when the APS criteria were modified from the previous Sapporo 
criteria after an international meeting in Sydney (3, 4, 69). There are, however, reports that 
titers below criteria cut-off can also be important. This could be true for obstetric APS in 
particular (30, 68, 70-72). 
1.4.5 The role of aPL IgM has been questioned 
The current APS criteria include positivity in both the IgG and IgM isotypes for aCL and anti-
β2GPI (3). However, the rationale for continuing to test for IgM as part of clinical risk 
stratification has been questioned since associations with events for aPL of IgM isotype seem to 
be generally weaker than for IgG isotype (73). 
The systematic reviews of aPL and thrombosis by Galli et al (23, 24) reported that IgM was less 
strongly associated with thrombosis in both the aCL and the anti-β2GPI-assays, but the authors 
stated that the subject could only partially be addressed as IgM antibodies were rarely studied 
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separately. After these systematic reviews, a number of prospective studies have confirmed that 
the clinical association between IgM isotype and thrombosis is dubious (7, 33, 74, 75). 
However, results are conflicting if other study designs are also included. Some of these studies 
present findings that could justify continuing IgM use, sometimes demonstrating isotype-
specific patterns of associations (76-81), while others report results that argue against further 
use of IgM aPL (65, 82-84).   
For obstetric manifestations, a metaanalysis of RFL among women without additional 
autoimmune disease showed a convincing association for IgM aCL as well as for IgG aCL, but 
the relationship with anti-β2GPI, regardless of isotype, was more uncertain (36). For SLE 
patients, studies reporting association with obstetric events for the two criteria-isotypes 
separately are hard to find. Julkunen et al studied the association between different aPL tests 
and a history of foetal loss in 107 SLE women and found that IgM aCL was the only individual 
test with a statistically significant OR: 3.0 (1.1-7.8) (42). 
1.4.6 The concept of multiple positivity and risk scores— the only way to go? 
Through all the controversies and difficulties in aPL testing, APS diagnostics and aPL-related 
risk stratification, a new concept with increasing popularity has emerged. Despite the 
weaknesses and dubious clinical association of the individual aPL tests, combining the results 
of multiple testing could provide a good strategy for risk estimation. The idea is that triple 
positivity in the criteria aPL assays, but not single positivity, confers a substantially increased 
risk for APS manifestations. The value of isolated positivity in the ELISA assays (aCL, anti-
β2GPI) has been particularly questioned (23, 24, 55, 73, 85-90). It should be noted that many 
of the clinical studies described in section 1.4.1 were not designed for/did not use the 
statistical method required to evaluate the risk associated with a single positive aPL test. 
However, the concept of multiple positivity is very important and has probably paved the way 
for attempts to develop new aPL risk scores (91-93). Ideally, such scores could guide 
treatment which in itself is not without risk (55). It is recognised that in this context, non-aPL 
factors also need to be taken into consideration (30, 94). In addition, there is an on-going 
debate about the value of antibody avidity (95) as well as of “non-criteria” aPL such as IgA 
aPL, antibodies against PT or phosphatidylserine-PT complex, and anti-β2GPI against domain 
I (50, 53, 96).  An association with triple positivity has been reported for anti-β2GPI against 
domain I (further discussed in section 1.5.1) (97). 
1.4.7 New methods in the pipeline?  
As stated in a recent review on the future of antiphospholipid antibody testing by de Groot 
and Urbanus: “Not only is there a need for better assay standardization, there is also a need 
for better assays” (55). 
More automated assays for aPL testing are being developed. Hopes for these methods are that 
they will be less time- and manpower-consuming, have improved reproducibility, and have 
reduced interlaboratory variation. A few years ago, the publications on the performance of 
these assays were scarce, but the body of literature on this subject is growing. The concept 
seems promising even though obstacles like the lack of a golden standard and uniform 
measurement units complicate the evaluation of the assays (98-105). 
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1.5 Exploring the largely unknown APS aetiology could provide clues to new 
biomarkers  
A better understanding of the still enigmatic APS pathophysiology can be regarded as a 
prerequisite for the development of better methods for risk assessment in APS (55). It could 
also guide more targeted therapies.  
The body of knowledge of APS aetiology is currently growing, supported by new important 
pieces of information from clinical APS studies as well as experimental aPL studies and 
through studies of conditions with similar clinical manifestations as APS.  
1.5.1 Many factors have been proposed to contribute to APS pathogenesis  
Five recent reviews of APS pathogenesis summarise prevalent hypotheses of APS pathogenesis 
(54, 106-109) as they emerge from a number of important original studies (some of which are 
cited below): 
• β2GPI is important. The physiological role of this plasma protein is unclear, but it has 
been proposed to act as a “vacuum cleaner,” involved in binding and clearance of 
injured and apoptotic cells, microparticles (MPs), and bacterial products (110-112). 
There are speculations that naturally occurring antibodies against this molecule are 
involved in its regulation and that the increased thrombotic risk observed in APS could 
be related to increased titer and avidity of such naturally occurring antibodies and/or 
their prolonged presence in the circulation. This hypothesis, put forward in one of the 
above mentioned reviews (108), is based on the finding that healthy individuals without 
APS can have memory B-cells that produce aPL (113). Moreover, molecular mimicry 
has been suggested as a mechanism for aPL production (114). 
• The B-cell epitope in domain I of the β2GPI molecule is especially interesting. Patients 
that are aPL triple positive have high titers of antibodies against this domain (97) and 
these antibodies confer LA activity associated with high risk of thrombosis (115). It has 
thus been suggested that APS is an autoimmune disease with a single type of 
autoantibody which can give rise to positive results in both aCL/anti-β2 GPI ELISAs and 
the LA test (97). 
• The structure and function of β2GPI can be affected by external factors. Infections, 
smoking, and pregnancy can cause increased oxidative stress which seem to modify the 
β2GPI molecule (116), affecting domain I with its important B-cell epitope (117). 
Moreover, β2GPI can exist in two different configurations with different exposure of the 
domain I epitope, depending on whether it is bound to an anionic surface or not (118). 
Conformational changes have recently been shown to occur after binding of ββ2GPI to 
bacterial proteins as well (119). Conformational changes affect the epitope recognition 
of anti-β2GPI domain I antibodies (120). 
• aPL are most likely pathogenic. Antibodies from patients with APS can potentiate the 
development of thrombosis when they are infused into mice, but this effect is lost when 
the anti-β2GPI component is eliminated (121) (122). 
• aPL presumably confer their effect through activation of specific receptors on target 
cells (see Figure 2). The binding of aPL to the target cells is mediated by their main 
autoantigen β2GPI. It is the complex of the antibody and the antigen that activates the 
cells. Target cells include endothelial cells (123), monocytes (124), neutrophils (125), 
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and platelets (126). aPL most likely  upregulates target cell expression of pro-adhesive 
and pro-coagulant molecules like intercellular adhesion molecule 1 (ICAM-1), vascular 
cell adhesion molecule 1 (VCAM-1), endothelial Selectin (E-Selectin), and tissue factor 
(TF) (125, 127-130). However, the mere presence of aPL or aPL complexes does not 
appear to be sufficient to cause thrombosis. In agreement with the proposed “two hit” 
hypothesis, there seems to be a need for priming or stimulation of the endothelium (122, 
131). Oxidative stress can upregulate the expression of annexin II (132) which is an 
important endothelial cell surface receptor for β2GPI (133).  
• Endothelial nitric oxide synthase (eNos) is probably a key player.  There are 
indications that aPL promote leukocyte-endothelial cell adhesion and thrombosis by 
antagonising eNOS (134). eNOS is upregulated by statins (135), drugs that prevent 
anti-β2GPI-mediated endothelial activation (136). 
• Several other pathogenic mechanisms for aPL/APS have been proposed. Suggested 
mechanisms include aberrations related to coagulation factors such as FXI (137), aPL 
interference with the protective annexin V shield (138, 139) and with the activity of 
anticoagulants such as Activated Protein C (APC) (140, 141) and Antithrombin III 
(142), complement activation (leading to activation of neutrophils and TF expression) 
(125), other disturbances of the innate immunity (143), and finally various abnormalities 
in the fibrinolytic systems (see section 1.5.3).  
• Pathogenic mechanisms behind obstetric and thrombotic APS are only partly 
overlapping. The main mechanism for the obstetric manifestations of APS was initially 
believed to be thrombosis, to some extent supported by histopathological findings in 
placenta from patients with intrauterine foetal death and aPL (144). However, further 
studies have suggested the importance of additional mechanisms such as defective 
trophoblast proliferation/invasion and decidual transformation in early pregnancy (145, 
146) as well as placental injury caused by local inflammatory events including 
complement activation (147, 148).   
A recent study by Canaud et al proposes that the mammalian target of rapamycin complex 
(mTORC) pathway is important in vascular lesions associated with APS and that this could 
have important therapeutic implications (149). 
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Figure 2: Schematic overview of potential antiphospholipid (aPL) mechanisms of action 
on coagulation 
a. Activation of endothelium, platelets, monocytes, and neutrophils resulting in expression of 
pro-adhesive and pro-coagulant molecules like tissue factor (TF). Exposure of pro-coagulant 
phospholipid (PL) phosphatidylserine (PS) through disruption of the protective annexin V 
shield 
b. Initiation of coagulation cascade by TF on PL-expressing cell surfaces onto which the 
calcium (Ca)-dependent coagulation factors can bind 
c. Aberrations related to coagulation factors and anticoagulants (Protein C, Antithrombin III) 
determining thrombin formation 
d. Disruption of the fibrinolytic system (fibrinogen/fibrin, fibrin network, 
plasminogen/plasmin, tissue plasminogen activator=tPA, plasminogen activator inhibitor-
1=PAI-1) 
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1.5.2 Is smoking important? 
Mechanistic studies have suggested that APS patients could be more sensitive to oxidative 
stress from exogenous sources such as smoking (54). A joint effect of aPL and smoking on the 
occurrence of cardiovascular events has been reported (9). There are few studies on the 
association between smoking status and aPL positivity, however. 
1.5.3 Are fibrin network characteristics and fibrinolysis relevant?  
Emerging evidence suggest that the formation of thrombi characterised by abnormal 
architecture (high fiber density, thin fibers, small pores) and decreased fibrin permeability 
demonstrated in in vitro assays is a feature of many conditions with increased risk for 
cardiovascular and thrombotic events (150-159). Such thrombi are associated with an increased 
resistance to fibrinolysis due to, for example, decreased permeability of fibrinolytic factors 
through the fibrin clot (160-163). Hypofibrinolysis is discussed as a risk factor for both venous 
and arterial thrombosis (164). 
The structure of fibrin formed in vitro can be visualised using different microscopic techniques. 
Fibrin permeability can be studied using a liquid permeation technique, originally developed by 
Blombäck et al (165, 166) and later subject to some modifications to facilitate its use (167). In 
normal haemostasis, conversion of fibrinogen to fibrin monomers is catalysed by thrombin, this 
is followed by polymerisation into protofibrils that in the presence of thrombin-activated FXIII 
subsequently form a cross-linked fibrin network/clot. The conditions prevailing during this 
process determines fibrin structure and function, such as permeability of the fibrin network. 
Factors of potential importance include: concentrations and variations of fibrinogen, fibrin(-
ogen) modulators (albumin, fibronectin, factor XIII, and cells present during coagulation), 
thrombin/thrombin generating factors, calcium and polyphosphate as well as pH, ionic strength, 
and local blood flow (159, 165, 168, 169). Moreover, MPs have been shown to bind fibrin (170) 
and to affect fibrin characteristics (171). Finally, fibrin permeability is increased by common 
cardiovascular therapies such as statins (171), dalteparin (172), ASA (173, 174), and warfarin 
(175). In the experimental models developed to study fibrin permeability (discussed above) 
where calcium and thrombin are added to plasma samples to start clot formation, some of the 
factors contributing to fibrin gel porosity are kept constant. Fibrin permeability thus depends 
mainly on the sample fibrinogen, an acute phase reactant that in itself is well known to be 
associated with cardiovascular disease (CVD) risk, but may also be affected by modulators in 
the investigated samples (166, 167, 176, 177).  
The fibrinolytic system is the final phase of normal haemostasis, when the fibrin clot is 
removed and the damaged vessel wall restored. It is activated and regulated by several proteins 
affecting the generation of the fibrin clot-degrading enzyme plasmin from plasminogen. The 
most important plasminogen activator in plasma and the main regulator of fibrinolysis is tissue 
plasminogen activator (tPA), which is produced by stimulated endothelial cells. When bound to 
fibrin, tPA is protected from its principal inhibitor in plasma: plasminogen activator inhibitor-1 
(PAI-1) which is produced by different cell types including endothelial cells, platelets and 
hepatic cells. α2-antiplasmin, the primary physiological inhibitor of plasmin, as well as FXIII 
and thrombin-activatable fibrinolysis inhibitor (TAFI) are other key players of the fibrinolytic 
system (164, 178, 179). Fibrinolysis can generally be investigated through assays measuring 
antigen or activity levels of various plasma components of the fibrinolytic system or by more 
global assays (180). Antigen levels of tPA, PAI-1, and tPA-PAI-1 complexes are important for 
CVD risk (181, 182). In global assays, overall hypofibrinolysis is associated with both arterial 
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and venous thrombosis (164). In turbidimetric assays, clot formation and lysis characteristics of 
plasma samples can be examined in vitro through addition of thrombin, calcium, and tPA (183). 
Though seldom studied, there are some reports that impaired fibrinolysis contributes to the pro-
coagulant state in APS (109). Hypofibrinolysis has been demonstrated using global in vitro 
assays in both obstetric (184) and thrombotic APS populations (185), but the underlying 
mechanisms are unclear. Antibodies blocking the ability of β2GPI to stimulate clot lysis have 
been suggested as a mechanism, while increased fibrinogen concentration as well as enhanced 
activity of factor XIII have been demonstrated in APS. Moreover, increased levels and activity 
of PAI-1 have been reported in patients with connective tissue diseases (109, 186-189). Clot 
architecture is another possible factor, which may affect fibrinolysis and coagulation 
equilibrium, but its role had not yet been investigated in patients with APS at the time when the 
studies presented here were conducted.  
1.5.4: Do microparticles play a role?  
Changes in the number or function of circulating MPs are associated with many disorders 
with arterial or venous thrombosis (190, 191) and pregnancy morbidity (pre-eclampsia and 
RFL) (192, 193) as well as various rheumatic diseases (194). It is thus reasonable to suspect 
that MPs have implications also for APS. 
 
 
  
Figure 3: Schematic presentation of a microparticle (MP) 
PS= Phosphatidylserine 
January 19, 2015 
 25 
MPs are small vesicles (0.1-1 µm) that upon activation or apoptosis are released from 
membranes of different cell types in a way that usually causes the anionic phospholipid 
phosphatidylserine (PS) to be exposed to the circulation, see Figure 3. Under normal 
conditions, platelet-derived MPs (PMPs) are by far the most abundant MPs in the blood. MPs 
are most often measured using flow cytometry. They are commonly identified using size and 
exposure of PS. PS exposure is frequently detected through annexin V binding (194) but can 
also be identified using lactadherin (195), a milk-fat protein that that binds to PS regardless of 
calcium levels. PS serves as a red flag for macrophage recognition and lactadherin is involved 
in the phagocytic elimination of activated or apoptotic cells (196) (197), and perhaps also of 
MPs. A mechanistic study suggests that binding of β2GPI to PS-expressing pro-coagulant 
PMPs may promote their clearance by phagocytosis and that autoantibodies to β2GPI may 
induce a pro-coagulant state by inhibiting this process (112). The number of circulating MPs 
is probably dependent on a dynamic balance between release and clearance (191). MPs are 
more prone to escape phagocytic clearance than for example the larger apoptotic bodies, and 
they express different surface, cytoplasmic, and nuclear molecules. Their surface and content 
depend on the parent cell type and the conditions during their release. MPs can thus be 
regarded as tiny messengers of previous or occurring cellular events. However, one must keep 
in mind that MP structure may be partly dynamic, as binding of for example 
immunoglobulins and complement proteins can take place not only before but also after 
detachment from the parent cells. MPs may provide information about tissues, like the 
endothelium, that otherwise could only be obtained through invasive biopsies. Furthermore, 
MPs can themselves have biological effects through signalling at both local and distant sites. 
Their pro-thrombotic potential is well-known. They provide an enlarged catalytic surface with 
negatively charged PS for the assembly of calcium-dependent procoagulant enzyme 
complexes. They can also express pro-coagulant entities such as TF (194). Furthermore, there 
are indications that MP could affect fibrinolysis. However, some MPs might also be pro-
fibrinolytic depending on protein exposure (191). 
MPs have a pro-inflammatory potential that can be of importance in many pathological 
conditions. Moreover, important contributions to disease pathogenesis can be made through 
MPs taking part in the formation of immune complexes. Particles generated through apoptosis 
can contain nuclear components, which in this way become more accessible to the immune 
system for example for antibody binding (194). Additionally, MPs can stimulate apoptosis, 
providing a positive feedback loop which amplifies the initial response (191, 198). 
There are to date relatively few previous studies of MP in aPL-associated disorders including 
SLE (studies are summarised in Table 2 and Table 3). Moreover, the majority of existing 
studies are small, seldom include obstetric patients, use non-uniform measurement-methods, 
and report inconsistent findings (198-213). Many studies demonstrate an increased number of 
different MPs in these conditions (199-202, 204-206, 209, 214), but a recent Danish study 
found an overall decreased number of annexin V positive MPs in SLE as compared to healthy 
controls. However, the authors reported the SLE patients did have an increased number of 
annexin V negative MPs, followed by a suggestion that this could have implications for 
phagocytic recognition (208). There are also indications that the number of circulating MPs 
could correlate (positively or negatively) with SLE disease activity (214, 215). It is, however, 
likely that not only the mere number of circulating MPs but also their composition and 
function is of importance in these contexts (216). 
In a review by Pericleous et al (198) it was suggested that aPL positivity could be enough to 
confer elevated levels of endothelial MPs (EMPs), but the properties of these EMPs may 
differ between the aPL carriers that are affected by thrombosis and those who stay 
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thrombosis-free. Consistent with this hypothesis, APS patients were recently reported to have 
higher MP-TF activity than asymptomatic aPL carriers (217).  
 
Table 2: Previous studies of microparticles in antiphospholipid Syndrome (APS) 
STUDY 
 
PATIENT 
POPULATION 
NUMBER OF APS-
PATIENTS/APL-
POSITIVE 
TYPE OF 
MICROPARTICLES 
CHANGE IN 
NUMBER OF 
MP: APS VS. 
HEALTHY 
CONTROL 
     
Combes et al 
1999 
LA-positive  30 (8 APS) EMPs ↑ 
Joseph et al 2001 APS (SLE) 20 PMPs → 
Dignant-George 
et al 2004 
APS, SLE+ aPL  111 (35 APS) EMPs ↑ 
Nagahama et al 
2003 
APS 37 MMPs/PMPs ↑ (for all MPs) 
Jy et al 2007 Persistently aPL-
positive  
88 (60 with thrombosis)  EMPs/PMPs ↑/→  
Flores-
Nascimento et al 
2009 
APS (DVT, FVL-
carriers) 
11 PMPs, EMPs, MMPs, 
ErMPs, LMPs 
→ (for all MPs) 
Antwi-Baffour  et 
al 2010 
aPL-positive, 
(SLE) 
13 Total MPs ↑ 
LA=Lupus anticoagulant. APS=Antiphospholipid syndrome. SLE=Systemic lupus erythematosus. aPL=Antiphospholipid antibody. FVL=!
Factor V Leiden. DVT=Deep venous thrombosis. EMPs=Endothelial microparticles. PMPs=Platelet microparticles. MMPs=Monocyte 
microparticles. ErMPs=Erytrocyte microparticle. LMPs=Leukocyte microparticle. 
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Table 3: Previous studies of microparticles in Systemic Lupus Erythematosus (SLE) 
 
STUDY PATIENT 
POPULATION 
NUMBER OF 
SLE-
PATIENTS 
TYPE OF 
MICROPARTICLES 
CHANGE IN 
NUMBER OF MP 
SLE VS. 
HEALTHY 
CONTROL 
Joseph et al 
2001 
SLE (APS) 30 PMPs → 
Nauta et al 
2002 
SLE 16 Total MPs → 
Pereira et al 
2006 
SLE 30 Total MPs/PMPs/LMPs/EMPs ↑/↑/↑/→ 
Sellam et al 
2009 
SLE (Sjögren, RA) 20 Total MPs/PMPs/ LMPs ↑/↑/→ 
Duval et al 
2010 
SLE 27 EMPs ↑ 
Antwi-Baffour  
et al 2010 
SLE  (APS) 20 Total MPs ↑ 
Oyabu et al 
2011 
Connective tissue 
disease 
88 PMPs → 
Ullal et al 2011 SLE 21 Total MPs → 
Nielsen et al 
2011 
SLE 70 
a. Total Annexin+ 
MPs/PMPs, 
LMPs/EMPs 
b. Total Annexin-MPs 
a.↓/ ↓/↓/→ b. ↑ 
Parker et al, 
2013 
SLE (active 
disease) 
27 EMPs ↑  
Crookston et al 
2013 
SLE 51 Total MPs, PMPs, MMPs, 
EMPs 
→ (for all MPs) 
APS=Antiphospholipid syndrome. SLE=Systemic lupus erythematosus. MPs=Microparticles.  EMPs=Endothelial microparticles. 
PMPs=Platelet microparticles. MMPs=Monocyte microparticles. LMPs=Leukocyte microparticles. 
 
 
 
 1.6 aPL are important for vascular disease in SLE   
As described in section 1.2, there is a close relationship and an overlap between APS and SLE. The overlap is 
clinical as well as immunological and genetic (218, 219). Like APS, SLE is in itself a heterogeneous and 
unpredictable disorder with incompletely understood, most likely multifactorial pathogenesis. An excess of 
apoptotic material in the circulation due to increased production and/or defective clearance is thought to be an 
important feature. This exposes nuclear components to immune cells, enabling production of autoantibodies and, 
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in genetically susceptible individuals, persistent autoimmunity (220). aPL has been suggested to play a role in 
these processes as a mediator of autoimmunity against dying cells (221). Whatever the exact aetiology, the 
production of a various autoantibodies is a hallmark of SLE, which together with a set of defined symptoms is 
used to distinguish SLE from other conditions (222). The first criteria for SLE were published in 1971 and 
criteria revisions were then proposed in 1982, 1997, and 2012. The 1982 criteria, which are used in this thesis, 
are presented in Table 4. Generally, all sets of classification criteria rely on a number of clinical and/or 
immunological manifestations. Clinical symptoms include serositis, haematological disorders, and 
manifestations from skin/mucosa, joints, the nervous system, and kidneys. Positive antinuclear antibodies 
(ANA), anti-double-stranded DNA (anti-dsDNA) and anti-Smith (anti-Sm) are important immunological criteria 
which in the updates have been accompanied by positive aPL (including aCL and anti-β2GPI of IgA isotype), 
low complement, and direct Coombs test in the absence of haemolytic anaemia (222-224). However, these 
criteria were designed to enable consistency between research studies and no specific diagnostic criteria exists 
(225). SLE is a rare disease with reported incidence ranging from 2.2 to 7.6 cases per 100 000 persons per year 
(226). Women are affected on average 6-8 times more frequently than men (225). Current treatment options 
include anti-malarials, steroids, and various immunosuppressive and biological agents (227). Even though 
morbidity and mortality have improved over the years, there is still a pronounced increase in overall mortality 
compared to the general population (226).  
 
Table 4: The 1982 American College of Rheumatology criteria for classification of SLE 
 
 If four of these criteria are present at any time during the cause of the disease, a diagnosis of SLE can be made.Sm= the Smith antigen. LE cell= 
lupus erythematosus cell. VLDR=Venereal Disease Research Laboratory. ANA=antinuclear antibodies. anti dsDNA=anti-double stranded DNA. 
 
Cardiovascular and thrombotic complications are responsible for a large part of the total 
morbidity and mortality in SLE. Traditional atherosclerotic risk factors, partly affected by 
immunosuppressive therapy, does not fully account for the increased vascular burden. Instead, 
Criteria Explanation 
1. Malar rash  
 
Fixed erythema over the malar eminences  
 
2. Discoid rash  
 
Erythematosus raised patches with adherent keratotic scaling and follicular plugging  
 
3. Photosensitivity  
 
Skin rash caused by unusual reaction to sunlight  
4. Oral ulcers  
 
Oral and nasopharyngeal  
 
5. Arthritis  
 
Non-erosive  
 
6. Serositis  
 
Pleuritis or pericarditis  
7. Renal disorder  
 
Persistent proteinuria or cellular casts  
 
8. Neurologic disorder  
 
Seizures or psychosis  
 
9. Haematologic disorder  
 
Haemolytic anaemia or leukopenia or lymphopenia or thrombocytopenia  
 
10. Immunologic disorder  
 
Positive LE cell preparation or anti-dsDNA or anti-Sm antibodies or false positive VLDR 
 
11. Antinuclear antibodies  
 
An abnormal titer of ANA by immunofluorescence or an equivalent assay  
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factors related to the chronic inflammatory disorder itself have proven to be of major 
importance (228-233). One such factor is aPL, which is a positive predictor of vascular events 
in several prospective studies (29, 30, 232, 234). An increased understanding of how these auto-
antibodies confer increased cardiovascular risk is hoped to aid the development of better 
biomarkers and methods for individual risk assessment and treatment in SLE patients, which are 
much needed (55).  
  30 
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2 AIMS 
To study clinical, serological and haemostatic features of APS and aPL-related disorders, 
including SLE, in order to improve and individualise patient care. Major objectives are: 
• To improve diagnostic methods for APS/aPL-related disease and identify new 
biomarkers 
• To enhance understanding of the pathogenesis behind APS/aPL-related disease with 
focus on the role of fibrin clot properties, fibrinolytic function, MP profile, and smoking 
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3 MATERIAL AND METHODS 
3.1 Study design and population  
3.1.1 Paper I 
This is a cross-sectional study including 712 patients clinically diagnosed with SLE during 
1984-2010 from the rheumatology clinics at Karolinska, Uppsala, and Lund University 
Hospitals (n=381, n=139, and n=192, respectively). For a clinical diagnosis of SLE, we required 
characteristic SLE serology in combination with a minimum of two typical organ 
manifestations and absence of more plausible explanations for the condition (235). The majority 
of the patients also fulfilled at least four of the 1982 revised classification criteria for SLE 
according to the American College of Rheumatology (ACR),  but 25 patients fulfilled less than 
four criteria (222). At inclusion, clinical information was collected by interviewing the patients 
and reviewing medical records. Blood samples were drawn. 
To calculate a cut-off level corresponding to the 99th and 90th percentile, we used samples from 
280 controls from the general population without any history of thrombosis or obstetric 
morbidity, as defined in the APS criteria (3). These individuals were matched to Karolinska 
patients for age, sex, and place of residence.  
Definition of clinical events 
The clinical APS manifestations studied were the following objectively verified vascular events: 
1) Ischaemic heart disease (IHD): MI confirmed by electrocardiography and a rise in plasma 
creatine kinase, muscle and brain fraction (CK-MB), or troponin T and/or angina pectoris 
confirmed by exercise stress test and/or coronary bypass intervention.  
2) Ischaemic cerebrovascular disease (ICVD): Stroke including cerebral infarction confirmed 
by computer tomography or magnetic resonance imaging and/or TIA, defined as transient focal 
symptoms from the brain or retina with a maximum duration of 24 hours.  
3) Ischaemic peripheral vascular disease (IPVD): Intermittent claudication and/or peripheral 
arterial thrombosis or embolus confirmed by angiogram or Doppler flow studies and/or surgical 
intervention of peripheral vascular disease. 
4) Venous thromboembolism (VTE): DVT, confirmed by venography or ultrasonography 
and/or PE, confirmed by pulmonary perfusion scintigram, angiogram, or spiral computer 
tomography. 
The term “any arterial event” (AAE) refers to the occurrence of one or more of events 1-3. The 
term “any vascular event” (AVE) refers to the occurrence of one or more of the events 1-4. 
We also tabulated obstetric morbidity, defined according to established APS criteria (i.e. 
miscarriages, premature birth, foetal death) (3), and thrombocytopenia, defined according to 
ACR criteria (222). 
3.1.2 Paper II and III 
Paper II and III are cross-sectional studies where patients fulfilling the APS criteria (3) from the 
Rheumatology, Haematology and Women’s and Children’s Health clinics at Karolinska 
University Hospital were asked to participate during a 1-year inclusion period starting January 
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2009. At inclusion, patients filled out a questionnaire supervised by a physician about 
symptoms and medications. Blood samples were drawn. Initially, 54 patients consented to 
participation but all were not included in the two studies as errors during sample handling and 
transport prevented all blood samples from being used. In study II, 49 of the APS patients were 
included, and in study III, 52 patients were included.  
According to criteria (3) aPL positivity was defined as at least two positive tests of 
medium/high titer for IgM aCL/IgG aCL, a titer >99th percentile for IgG anti-β2GPI,  or a 
positive LA test. Confirmation tests were performed after a minimum of 12 weeks. We also 
required at least 12 weeks and no more than 5 years between positive testing and the clinical 
manifestation. In both studies, 12 of the patients had secondary APS but the majority were 
primary APS patients (37 patients in paper II and 40 patients in study III).  
In paper II, we compared the APS patients with two different control groups. The primary 
control group consisted of 19 healthy individuals recruited through our laboratory. All of them 
were instructed to avoid non-steroidal anti-inflammatory drugs (NSAID) or ASA at least two 
weeks prior to the study. The second control group comprised 39 non-APS thrombosis patients, 
all treated with warfarin at our coagulation unit. These control groups will be referred to in this 
thesis as healthy controls (HCs) and non-APS thrombotic controls (non-APS TCs), respectively. 
In paper III, 52 healthy, non-NSAID/ASA-treated individuals recruited as in study II served as 
the control group. The control groups in study II and III were partly but not completely 
overlapping.  
3.1.3 Paper IV and V 
The participants in study IV and V are from the Karolinska SLE cohort. All patients in this 
cohort fulfilled at least four of the 1982 revised ACR criteria for SLE (222).The study 
population in these two cross-sectional studies thus overlaps with the participants in study I and 
we used the same definitions for clinical events as in study I. 
In study IV, we only included patients from whom MP data was available for both patients and 
their respective matched controls. Two hundred ninety SLE patients who received care at the 
Department of Rheumatology, Karolinska University Hospital in Solna in 2004-2011 were 
included. As controls, 290 “SLE-free” individuals identified through the Swedish national 
population registry and matched to the SLE patients for age, sex and place of residence were 
included.  
In study V, 367 SLE patients who received care at the Department of Rheumatology, 
Karolinska University Hospital in Solna in 2004-2010 were included. 
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Figure 4: Overview of patients investigated in study I-V 
SLE=Systemic lupus erythematosus. APS= Antiphospholipid syndrome. 
 
3.2 Laboratory investigations 
3.2.1 ELISA methods for detection of aPL and LA test 
In this thesis, testing for specific aPL, i.e. aCL and anti-β2GPI, was generally carried out 
according to clinical standard, using indirect ELISAs. In brief, the principles of these assays 
(see Figure 5) are that the antigens (β2GPI for the anti-β2GPI test or CL+β2GPI for the aCL 
test) are bound to wells in microtiter plates and non-specific binding sites are blocked, after 
which and patient samples are added. If aPL is present in the patient sample, it will bind to the 
solid phase. The plate is then washed to remove unspecific serum and plasma components and 
an antihuman IgG/M-antibody labelled with an enzyme is added. Unbound reagent is 
removed by washing and the substrate for the bound enzyme is added. If a reaction 
subsequently occurs, a colour change is yielded and the bound antibodies can be detected 
spectrophotometrically (236, 237). 
In paper I, IgG aCL and IgM aCL as well as IgG anti-β2GPI  were analysed by a routinely 
performed ELISA (Orgentec, Mainz, Germany) and a new fully automated fluorescence 
enzyme immunoassay method (Elia Cardiolipin IgG, Elia Cardiolipin IgM, and Elia β2-
Glycoprotein I IgG performed on Phadia 250, Phadia AB, now Thermo Fisher Scientific, 
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Germany), according to the manufacturer’s descriptions. With the latter method, IgM anti-
β2GPI  was also analysed (Elia β2-Glycoprotein I). The two methods are, when compared in this 
thesis, referred to as the routine ELISA method (RM) and the automated method (AM).  
In paper II, III, IV and V, IgG aCL, IgM aCL and IgG anti-β2GPI were analysed by the 
routinely performed ELISA (Orgentec, Mainz, Germany) as described above. 
Anti-β2GPI IgM was determined in paper IV and V and IgA aCL and IgA anti-β2GPI  were 
determined in paper V with a multiplex immunoassay, Bioplex 2200 APLS IgG, IgM, and IgA 
(Bio-Rad Laboratories, Hercules, CA, USA).  
 
 
 
Figure 5: Principles of antiphospholipid (aPL) ELISA testing 
 
The primary method for LA determination in this thesis was a dRVVT method. Reagents from 
Biopool, Umeå, Sweden and Gradipore, North Ryde, Australia were used in accordance with 
standard procedure. Patient samples were diluted 1:1 with normal plasma and clotting time was 
measured with addition of the LA reagent and compared to the clotting time for normal plasma. 
As a confirmation test, excess phospholipids were added. LA was considered positive if a 
normalisation of the clotting time was achieved according to the local cut-off. In February 2010, 
we began to routinely use a new testing method at our clinic. This method uses two integrated 
tests (one dRVVT and one APTT) but skips the routine mixing with normal plasma. However, 
since most samples were analysed before February 2010, only a very small percentage of our 
patients’ samples were analysed according to this new method.  
3.2.2 Fibrin network permeability 
In this work, the fibrin permeability was examined using a liquid permeation technique 
originally described by Blombäck et al (165, 166) and later modified according to He et al in 
2005 (167). In brief, plasma samples are dialysed against a dialysing buffer to ensure constant 
ionic strength in all examined samples. The buffer also contains the fibrinolysis inhibitor 
aprotinin. Subsequently, CaCl2 and thrombin, the latter in relatively high concentration, are 
added. The mixture is left in plastic cylinders overnight so that clots can be formed. A buffer is 
then passed through the clots at different pressures and the amount of fluid that has permeated 
the fibrin gels at a given time is recorded and used to calculate a specific permeability constant 
(Darcy constant, Ks). A low Ks value indicates less permeability and a tighter fibrin clot (166, 
167).  
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In study II, blood samples from the 49 APS patients and 19 HCs were centrifuged at room 
temperature to receive platelet-poor plasma (for 20 min at 2570 and 2000 g, respectively) which 
was then dispensed into aliquots and stored at -70ºC to -80ºC. Blood samples from the 39 non-
APS TCs were also centrifuged (15 min at 2000 g) prior to storage at -70ºC to -80ºC. The APS-
patient plasma samples, samples from HCs, and samples from non-APS TCs (total volume 500 
µL) were dialysed at 4ºC against dialysing buffer (pH 7.4, 0.05 mol/L Tris, 0.1 mol/L NaCl 
(VWR, number: 16404-1), 1 mmol/L ethylenediamine tetraacetic acid (EDTA) (Fisher 
Scientific, Stockholm, Sweden), 5 KIU/mL aprotinin (standard drug ordered from Swedish 
pharmacy)) for 3 hours, with change of outer fluid at 1-hour intervals. Subsequently, 200 µL of 
dialysed plasma were transferred into plastic test tubes and 10 µL of CaCl2 (440 mmol/L) and 
10 µL of thrombin (Sigma Aldrich, St. Louis, MO, USA) (4.5 IU/mL) were added. Plasma was 
mixed and immediately transferred into small plastic cylinders where the fibrin clots were 
formed. The final concentrations of CaCl2 and thrombin were 20 mmol/L and 0.2 IU/mL, 
respectively. The clots were left in a moist atmosphere overnight in order to allow clot 
formation in all samples. Thereafter, percolating buffer (pH 7.4, 0.02 mol/L Tris, 0.02 mol/L 
imidazole (Fisher Scientific, Stockholm, Sweden), 0.1 mol/L NaCl) was allowed to pass 
through the clots at 5 different hydrostatic pressures and the volume of collected eluate was 
measured after an indicated time (167). Ks (in cm2) was calculated from the equation given by 
Carr et al in 1977. As seen in Figure 6, the parameters determining the constant are: the volume 
(Q, in cm3) that passed through over time (t, in seconds), viscosity of the liquid (H, in dyne x 
seconds), gel length (L, in cm), internal area of the cylinder (A, in cm2), and hydrostatic 
pressure (ΔP, in dyne) (238, 239). For 49 APS patients, 19 HCs, and 38 non-APS TCs, Ks could 
be calculated and used in the subsequent analysis.  
Figure 6: Principles of fibrin permeability assay (240) 
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3.2.3 Turbidimetric clotting and lysis assays 
In this thesis, fibrin clot density and overall fibrinolysis function were analysed by a 
turbidimetric clotting and lysis assay previously described by Carter et al (183). 
In study II, 49 APS patients, 19 HCs and 39 non-APS TCs were investigated with this assay. 
Two APS patients (one with a history of arterial thrombosis, both treated with dalteparin) were 
excluded from the analysis since no clotting reaction was initiated in the analysis of their 
samples. Plasma samples from 47 APS patients, 19 HCs, and 39 non-APS TCs were eventually 
included in the analyses. 
For the turbidimetric clotting assay, 75 µl of assay buffer (pH 7.4, 0.05 mol/L Tris-hydrochloric 
acid, 0.15 mol/L NaCl) was added to 25 µl of citrated plasma (in duplicate) in a microtiter plate. 
Fifty µl of a mixture of thrombin (final concentration 0.03 IU/mL) and CaCl2 (final 
concentration 7.5 mmol/L) was added to each well of a microplate and the absorbance at 340 
nm was read every 18 sec (240 cycles for each sample). The turbidimetric lysis assay was 
carried out in the same way as the clotting assay, but with the addition of recombinant, single-
chain tPA (activity at least 400 000U/mg, Technoclone GmbH, Vienna, Austria) to 75 µl of the 
assay buffer (final concentration of recombinant tPA 83 ng/mL). Both assays were run 
simultaneously in the same plate.  
From the turbidimetric clotting assay, the following variables, based on previous studies (183), 
were measured:  
1) Lag time C (LagC): the time at which an exponential increase in absorbance occurred. 
2) ΔMaximum absorbance 50 (ΔMaxAbs 50C): the highest absorbance value minus the 
absorbance at the baseline level. This variable was determined at the plateau phase 
reached at 50 min for all patients.  
From the turbidimetric lysis assay, the following variables were measured:  
1) Lag timeL (LagL): the time at which an exponential increase in absorbance occurred.  
2) Lys50t0: the time from the addition of thrombin and calcium to the time at which 
50% fall in absorbance from ΔMaximum Absorbance (Maximum Absorbance 
minus baseline) in the lysis assay (ΔMaxAbsL) is achieved.  
3) Lys50C: the time between a 50% increase and a 50% decrease in ΔMaxAbsL.  
4) Lys 50MA: the time from ΔMaxAbsL to the time at which 50% reduction in 
absorbance has occurred.  
 
3.2.4 Scanning electron microscopy 
In study II, the structure of the fibrin network was studied using scanning electron microscopy 
(SEM). Electron microscopy is a microscopy technique that uses electrons instead of light for 
the imaging of objects, allowing much smaller structural details to be visualised. Two main 
variants exists: transmission electron microscopy (TEM) and scanning electron microscopy 
(SEM). In SEM, an image is formed point by point using a focused electron beam to scan the 
surface of a solid specimen (241). 
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In our study, three clots formed in assays from APS patient plasma and one clot formed in assay 
from HC plasma were fixed in 2% glutaraldehyde in HEPES-buffered saline (HBS) (Medicago, 
Uppsala, Sweden) for 60 min at room temperature and then stored at 4ºC. The specimens were 
briefly rinsed in distilled water and placed in 70% ethanol for 10 min, 95% ethanol for 10 min, 
absolute ethanol for 15 min, and pure acetone for 10 min at room temperature and then 
transferred to tetramethylsilane (Merck, Darmstadt, Germany) for 10 min and air-dried. After 
drying, the specimens were mounted on an aluminium stub and coated with carbon (Bal-Tec 
MED 010, Balzers, Lichtenstein). The specimens were studied in an Ultra 55 field emission 
scanning electron microscope (Carl Zeiss, Oberkochen, Germany) at 3 kV(242) .  
3.2.5 Determination of MPs by flow cytometry 
In study III and IV, MPs were studied using a Beckman Coulter Gallios flow cytometer as 
described previously by Mobarrez et al (243, 244) (see Figure 7). The overall principle of MP 
determination by flow cytometry is that particles in samples incubated with fluorescent 
antibodies are passed through a laser beam while the light scattered and emitted from each 
particle is recorded. Through this procedure, particles can be characterised by size, complexity, 
and phenotype (220, 245).  
In paper III, we defined MPs as particles <1.0 µm in size, negative to phalloidin-Alexa 660 (a 
cell-fragment marker, which binds to intracellular actin; Invitrogen, Paisley, United Kingdom), 
positive to lactadherin-FITC (binds to PS; Haematologic Technologies, VT, USA), and positive 
to either CD42a-PE (PMPs; BD, NJ, USA), CD14-PC7 (monocyte MP=MMPs; Beckman 
Coulter, CA, USA), or CD144-APC (EMPs; AH diagnostics, Stockholm, Sweden). Moreover, 
exposure of CD142-PE (TF; BD, NJ, USA) was measured on EMPs. Conjugate isotype-
matched immunoglobulins (IgG1-FITC, IgG1-PE, IgG1-PC7 and IgG1-APC) with no reactivity 
against human antigens were used as negative controls. In the present study, results are 
presented as absolute numbers of MPs: (MPs counted * standard beads added/L)/standard beads 
counted (FlowCount, Beckman Coulter, CA, USA). The MP gate was set using Megamix beads 
(0.5 µm, 0.9 µm, and 3.0 µm; BioCytex, Marseille, France). Analysis were conducted on 
thawed citrate plasma from patients and controls that had previously been drawn, centrifuged 
(for 20 min at 2570 and 2000 g, respectively) and stored at -70 ºC to -80 ºC. Prior to flow 
cytometry analysis, the samples were again centrifuged at 2000 g for 20 min and the 
supernatant was then re-centrifuged at 13 000 g for 2 minutes at room temperature. The 
supernatant was then used for the MP analysis.  
In paper IV, the method for MP detection was similar to the method used in paper III with the 
same markers for cell fragments, PS exposure, EMPs, and TF. As a marker for platelets, CD41-
PE  (Abcam, Cambridge, United Kingdom) was used. CD45-PC7 (Beckman Coulter, Brea, CA, 
USA) was used for leukocytes,  CD154-APC (BD, San Jose, CA, USA) for CD40 ligand 
(CD40L),  CD106-PE (AH diagnostics, Stockholm, Sweden) for VCAM-1, and anti-C4d-FITC 
(ALPCO Diagnostics, Salem, NH, USA) for C4d. High-mobility group protein B1 (HMGB1) 
(anti-HMGB1-PE; R&D Systems, Minneapolis, MN, USA) was also measured. Measurement 
of C4d was not performed in the presence of lactadherin, as they are both conjugated with FITC 
dye. Thus, both PS+ and PS- MPs were included when C4d-expressing MPs were counted. 
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Figure 7: Schematic overview of flow cytometry detection of microparticles (MPs) in 
study III and IV 
3.2.6 Other laboratory measurements 
For the 49 APS patients in paper II, fibrinogen concentrations in plasma were measured using a 
BN Prospec nephelometer (Dade Behring, Deerfield, IL, USA) with reagents from the same 
manufacturer. For the 39 non-APS TCs and 17 HCs, fibrinogen concentrations in plasma were 
analysed using a Sysmex® CS2100i (Sysmex, Kobe, Japan) with reagent Dade Thrombin from 
the Siemens Healthcare Diagnostics Inc (Tarrytown, NY, USA). High-sensitivity C-reactive 
protein (hsCRP) was measured using a Beckman Coulter Synchron LX system Chemistry 
Analyser with reagents and calibrators supplied by Beckman Coulter Inc. (Sydney, NSW, 
Australia).  
3.3 Statistical analyses  
All statistical analyses were performed using JMP software (SAS Institute, Carey, NC, USA) or 
Statistical Analysis System (SAS). A p-value <0.05 was considered statistically significant. 
The Kappa coefficient was used for analyses of agreement between aPL tests. Calculations of 
OR with 95% confidence interval (CI) were used to compare the performance of the aPL tests in 
a clinical setting. Chi-square test or Fisher’s exact test were used for comparisons of categorical 
variables. For continuous variables, comparisons were made using t-tests/ANOVA in the case of 
normally distributed data and Mann-Whitney U test (Wilcoxon rank sum test) in the case of 
non-normal distributions. Spearman’s correlation coefficient (r) was used as a nonparametric 
measure of the correlation between continuous variables. Multivariable logistic regression 
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models were performed to analyse any association between a dependent dichotomous variable 
and multiple predictor variables.  
In paper IV, data was log transformed, if necessary, to obtain a normal distribution. Patients and 
matched controls were then compared with paired tests; McNemar’s test or paired t-test 
depending on data type. Association between MPs and clinical and laboratory characteristics 
were analysed with linear regression or t-test. 
In paper V, restriction was used as a method to assess possible effect modification. Stratified 
analyses and sensitivity analyses were performed to investigate the possibility of reverse 
causation explaining the associations between former smoking and aPL. Interaction between 
ever smoking and aPL for the risk of events was assessed with departure from additivity of 
effects as the criterion of interaction (246). The attributable proportion due to interaction (AP) 
was computed with 95% CI (247). 
Some of the studies in this thesis include a rather high number of conducted analysis. Since we 
tested a number of predetermined hypothesis no correction for multiple comparisons was made. 
Therefore it is justified to treat associations that are borderline statistically significant with some 
caution. 
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4 RESULTS 
4.1 Paper I 
4.1.1 Agreement between the two methods for aPL testing 
The cut-offs recommended by the manufacturer were generally higher than the 90th percentile 
cut-off but lower than the 99th percentile cut-off of our controls. 
We used data from the 331 patients with continuous values to calculate the Kappa coefficients 
for cut-offs corresponding to the 99th and 90th percentile, while all 712 patients were used to 
calculate the Kappa coefficient for the cut-offs corresponding to the manufacturer’s 
recommendation. Kappa values ranged from 0.16-0.71. For IgG aCL , IgM aCL,  and IgG anti-
β2GPI, agreement between the two methods were best using the manufacturer’s recommended 
cut-off.  
4.1.2. Association between different aPLs and vascular events and the impact of different cut-
offs for positivity 
ORs for the associations with previous vascular events using cut-offs corresponding to the 99th 
and 90th percentile (n=331) and the manufacturer’s recommendation (n=712) for single-positive 
aPL-tests as well as for double positivity are presented in Table 5.  
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Table 5: Associations between the aPL tests and thrombosis, using different cut-offs  
 
OR (95% CI) for thrombotic manifestations using the Routine method (RM) and Automated method (AM) respectively with cut-offs corresponding to the  99th 
percentile and 90th percentile of controls (n=331) and manufactures recommendation (n=712) as well as OR for Lupus anticoagulant (LA) (n=380 ). 
aPL=Antiphospholipid antibody. aCL=Anticardiolipin. anti-β2GPI = Anti-β2 glycoprotein-I. IgG=Immunoglobulin. N=Number. Ns=Non-significant. 
Test Any thrombosis Arterial thrombosis Ischaemic heart Disease (IHD) Ischaemic cerebrovascular disease (ICVD) Venous thrombosis 
IgG aCL (RM)      
99th percentile 1.9 (1.03-3.4) Ns Ns Ns 3.1 (1.6-6.0) 
90th percentile 2.3 (1.4-3.8) Ns Ns Ns 2.9 (1.6-5.1) 
Manufacture 2.3 (1.6-3.5) 1.6 (1.01-2.5) Ns 2.1 (1.2-3.6) 2.6 (1.7-4.1) 
IgG aCL (AM)      
99th percentile Ns Ns Ns Ns Ns 
90th percentile 1.8 (1.1-3.1) Ns Ns Ns 3.1 (1.7-5.6) 
Manufacture 2.2 (1.4-3.2) 1.6 (1.02-2.5) Ns 2.2 (1.3-3.9) 2.7 (1.7-4.2) 
IgG anti-β2GPI  (RM)      
99th percentile Ns Ns Ns 2.9 (1.1-7.7) 2.6 (1.1-6.1) 
90th percentile 2.0 (1.2-3.3) Ns Ns Ns 2.7 (1.5-4.8) 
Manufacture 2.2 (1.5-3.2) 1.7 (1.1-2.5) Ns 2.1 (1.2-3.5) 2.6 (1.7-4.0) 
IgG anti-β2GPI  (AM)      
99th percentile Ns Ns Ns Ns Ns 
90th percentile Ns Ns Ns Ns 2.5 (1.4-4.4) 
Manufacture 2.1 (1.4-3.1) 1.6 (1.02-2.5) Ns 2.6 (1.5-4.5) 2.1 (1.3-3.4) 
IgM aCL  (RM)      
99th percentile 1.8 (1.03-3.2) Ns Ns Ns Ns 
90th percentile Ns Ns Ns Ns Ns 
Manufacture 1.7 (1.2-2.5) 1.7 (1.1-2.6) 1.7 (1.02-3.0) Ns Ns 
IgM aCL (AM)      
99th percentile Ns 2.4 (1.05-5.3) 2.7 (1.002-7.2) Ns Ns 
90th percentile Ns Ns 2.3 (1.1-4.7) Ns Ns 
Manufacture Ns 1.6 (1.03-2.4) Ns Ns Ns 
IgM anti-β2GPI  (AM)      
99th percentile Ns Ns Ns Ns Ns 
90th percentile 2.0 (1.3-3.2) 2.1 (1.2-3.5) 4.8 (2.2-10.3) Ns Ns 
Manufacture  1.6 (1.06-2.5) 1.7 (1.05-2.7) Ns Ns Ns 
Double positivity (RM)      
99th percentile 2.0 (1.01-4.0) Ns Ns Ns 2.7 (1.3-5.6) 
90th percentile 2.4 (1.5-3.9) 1.8 (1.1-3.1) Ns Ns 2.6 (1.5-4.6) 
Manufacture 2.5 (1.7-3.7) 1.8 (1.2-2.8) Ns 2.4 (1.4-4.1) 2.9(1.8-4.5) 
Double positivity (AM)      
99th percentile Ns Ns Ns Ns Ns 
90th percentile 2.2 (1.3-3.7) Ns Ns Ns 2.5 (1.4-4.6) 
Manufacture 2.6 (1.7-4.0) 2.0 (1.3-3.3) Ns 3.0 (1.7-5.3) 2.6(1.6-4.3) 
LA 5.4 (3.1-9.4) 3.1 (1.7-5.6) Ns 5.0 (2.5-10.0) 4.3 (2.3-8.0) 
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4.1.3. Comparison between the specific aPL tests and the LA test regarding association with 
vascular events 
For comparison, OR for LA, using data from the 380 Karolinska patients, are also shown in 
Table 5. When we compared a positive LA test to double positivity with any of the two specific 
aPL methods using the manufacturer’s recommended cut-off, OR for any vascular event was 
approximately twice as high.  
4.1.4. Associations between aPL tests and other clinical features of APS 
Data on obstetric morbidity as defined in the APS criteria (3) were available for 296 female 
patients from Karolinska: 50 patients (17%) had experienced such events. Of the aPLs 
measured, merely IgG aCL (RM) and LA were associated with obstetric APS manifestations: 
OR 2.3 (95% CI 1.2-4.7) and 2.2 (1.1-4.4), respectively. 
A substantial proportion of the SLE patients  (142 out of 712) had presented with 
thrombocytopenia. IgG aCL (RM), IgG anti-β2GPI (RM), IgG anti-β2GPI (AM), and LA were 
associated with thrombocytopenia: ORs 1.8 (1.2-2.8), 1.6 (1.0-2.5), 1.8 (1.1-2.8) and 2.4 (1.4-
4.4), respectively. 
4.2 Paper II  
4.2.1 Fibrin porosity and concentration of fibrinogen 
Ks values for the APS samples were lower compared to both HC samples and non-APS TCs 
samples (p<0.0001 for both), see Table 6.  
 
Table 6: Fibrin network porosity and turbidimetric results in patients vs. controls  
P-value<0.05 using Mann-Whitney U test is interpreted as a significant difference between the groups. Values are given as median (interquartile 
range). Ns=Non-significant difference between the groups. ΔMaxAbs 50C = Maximum Absorbance at 50 minutes minus baseline level. Lys50t0 = 
the time from the addition of thrombin and calcium to the time at which 50% fall in absorbance from ΔMaximum Absorbance in the turbidimetric 
lysis assay (ΔMaxAbsL) occurred. Lys50C = the time between a 50% increase and fall in ΔMaxAbsL in the turbidimetric lysis assay. Lys 50MA = 
the time from ΔMaxAbsL to the time at which 50% reduction in absorbance occurred in the turbidimetric lysis assay. LagC = the time at which an 
exponential increase in absorbance occurred in the turbidimetric clotting assay. LagL =the time at which an exponential increase in absorbance 
occurred in the turbidimetric  lysis assay. 
Parameter, unit APS Patients Healthy 
controls  (HCs) 
NonAPS thrombosis 
controls (non-APS 
TCs) 
P-value APS 
vs. HCs  
P-value APS vs. non-
APS TCs  
Ks, cm2x10-9 (n=49+19+38) 6.3 (4.7-7.5) 10.2 (7.4-12.1) 11.7 (8.6-15.2) <0.0001 <0.0001 
ΔMaxAbs 50C, Absorbance 
Units (n=47+19+39) 
0.41 (0.36-0.47) 0.34 (0.32-
0.38) 
0.50 (0.44-0.56) 0.006 0.0003 
Lys50t0, seconds   
(n=47+19+39) 
1980(1746-2529) 1596 (1533-
1914) 
1817(1682-1980) 0.002 0.01 
Lys50C, seconds  
(n=47+19+39 
1456 (1170-
1850) 
1207 (1124-
1494) 
1412(1301-1583) Ns Ns 
Lys 50MA ,seconds 
(n=47+19+39) 
967 (765-1195) 847 (779-1042) 1000(863-1113) Ns Ns 
LagC , seconds (n=47+19+39) 374 (330-409) 280 (246-297) 246(208-272) <0.0001 <0.0001 
LagL, seconds  (n=47+19+39) 381 (333-445) 276 (252-306) 257(229-294) <0.0001 <0.0001 
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Plasma fibrinogen concentrations were higher in APS patients as compared to both HC and 
non-APS TCs (p<0.0001 for both). However, both fibrinogen and Ks values remained 
independently associated with group assignment in a multivariable adjusted analysis (p=0.005 
for Ks in the first model comparing APS vs. HC, p=0.001 for Ks in the second model 
comparing APS vs. non-APS TCs).   
Within the APS group, IgM aCL and dalteparin treatment were inversely associated with fibrin 
network tightness (p=0.007 and p=0.049, respectively). Apart from these two associations, the 
Ks values did not vary depending on differences in treatment, clinical APS manifestations, or 
the aPL test supporting the diagnosis at inclusion. The Ks values also did not correlate with age 
(r= 0.02, p>0.05, n=49), CRP (r=-0.18, p>0.05, n=45), fibrinogen concentration (r=-0.28, 
p>0.05, n=49), antibody titer (IgM aCL : r=0.15, n=46; IgG aCL r=0.13, n=47; IgG anti-β2GPI , 
r=0.16, n=47, p>0.05 for all), or number of MPs (r=0.15, 0.04, 0.02, -0.06 and 0.10 for MPs 
positive for lactadherin, Cd42a, Cd144, Cd14, and TF+Cd144 respectively, n=49, p>0.05 for 
all).  
4.2. SEM 
The fibrin structure in the SEM images from the APS samples was more compact with smaller 
intrinsic pores when visually compared to the image from the control sample. Moreover, the 
fibres in the APS samples were thinner with increased branch-points. The SEM image from an 
APS sample and the image from the control sample are shown with the same magnification 
(200 nm) in Figure 8. 
 
A. B. 
 
Figure 8: Scanning electron microscopy images (SEM) of fibrin network in one healthy 
control sample (A) and one representative sample from a patient with antiphospholipid 
syndrome (APS) (B) 
January 19, 2015 
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4.2.3 Turbidimetric clotting and lysis assays 
Results from the turbidimetric clotting and lysis assays are shown in Table 6. In the 
turbidimetric lysis assay, the results of the various assessments of lysis of fibrin fibrils (Lys50t0, 
Lys50C, Lys 50MA) were not uniform. For Lys50C and Lys 50MA, there was no difference 
between APS patients and the two control groups, respectively.  
Within the APS group, longer clot lysis times were observed in the subgroup with previous 
arterial events compared to the rest of the patients (p=0.01, 0.006, and 0.008 for Lys50t0 , 
Lys50C, and Lys 50MA, respectively). To further investigate this, we compared the APS 
subgroup with history of an arterial thrombosis (n=15) to the HCs and the non-APS TCs . We 
then found a more distinct difference with longer clot lysis time in the arterial APS subgroup as 
compared to both control groups. For all three lysis parameters, a difference between APS 
patients with arterial events and the two control groups were found (p<0.05 for all analyses). 
4.3 Paper III  
4.3.1 Microparticle measurement 
The number of total lactadherin-positive MPs, EMPs, TF-positive EMPs, and MMPs in samples 
from APS patients were increased compared to healthy controls (p<0.001 for all analyses). 
There was no significant difference between the number of PMPs in APS samples compared to 
control samples (p=0.13).  
APS patients also had a higher proportion of MPs negative to lactadherin as compared to 
healthy controls (p<0.001). 
4.3.2 Microparticles and clinical associations 
Neither the number of lactadherin-positive nor the proportion of lactadherin-negative MPs 
differed between different clinical manifestations or treatments (p>0.05 for all analyses).  
4.4 Paper IV 
4.4.1 Microparticle measurement 
All PS+ MPs were more frequent in SLE patients compared to matched controls (p<0.0001); 
numbers were roughly three times higher in the SLE patients. Platelet-derived MPs, endothelial-
derived MPs, and leukocyte-derived MPs were 2-3 times more frequent in patients compared to 
controls (p<0.0001, Figure 9 and Table 7). The activation and inflammation markers CD40L, 
VCAM-1, TF, and HMGB1 expressed on MPs were also higher in SLE patients (p<0.0001). 
C4d-expressing PMPs and EMPs were nearly 10 and 5 times higher, respectively, in patients as 
compared to controls. 
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 Figure 9. Number of total PS+ microparticles (MPs), platelet microparticles (PMPs), 
leukocyte microparticles (LMPs) and endothelial MPs (EMPs) in SLE patients and controls. 
Microparticles were measured on a flow cytometer and phenotyped according to cellular origin. The figure shows numbers of all PS+ MPs, 
platelet MPs (PMPs), leukocyte MPs (LMPs) and endothelial MPs (EMPs) in SLE patients and controls. Line indicates median value. Log 
transformation was performed, when needed, to ensure normally distributed data, after which a Paired T-test was used to compare groups,  *** 
= p<0.0001.  
January 19, 2015 
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Table 7: Number of microparticles in 290 SLE patients vs. 290 matched non-SLE controls 
 
Microparticles  
 
SLE  
median, (IQR) 
Controls  
median, (IQR) 
P-value 
PS+ MPs  25 487 (18 898-34 016) 8 613 (5 218-11 535) 2.9x10-80 
PMPs# 12 845 (9 342-17 504) 6 042 (3 519-8 716) 8.3x10-55 
PMPs + CD40L 1 196 (842-1 588) 328 (163-508) 1.2 x 10-76 
PMPs +C4d 4 576 (2 250-7 239) 467 (341-637) 1.7x10-85 
EMPs# 2 306 (1 638-3 506) 633 (376-883) 9.8x10-75 
EMPs +VCAM-1# 300 (168-548) 138 (88-200) 4.1x10-33 
EMPs + C4d 1 083 (672-1 477) 270 (122-575) 4.2x10-63 
EMPs + TF 778 (453-1253) 171 (106-322) 5.9x10-33 
LMPs# 1 678 (1 166-2 568) 636 (337-983) 2.2x10-45 
LMPs +TF# 583 (356-1 038) 344 (197-530) 1.6x10-18 
MMPs+ HMGB1 1 529 (914-2 188) 500 (232-862) 1.1x10-47 
#Calculations performed on values that were logarithmically transformed in order to obtain a normal distribution. Paired t-test was used to 
compare groups. PS+=Phosphatidylserine positive. MP=Microparticle.!PMPs= Platelet microparticles. EMPs= Endothelial microparticles. 
LMPs=Leukocyte microparticles. MMPs= Monocyte microparticles. TF=Tissue factor. CD40L=CD40 ligand. VCAM-1=Vascular cell adhesion 
molecule 1. HMGB1=High-mobility group protein B1. IQR=Interquartile range: 25th percentile-75th percentile. N=number.  
 
4.4.2 Microparticles and clinical association 
Based on the MP definition in this study, we examined if MP profile could be used to 
distinguish between SLE patients with or without APS or between SLE patients with or without 
AVE. We performed multivariable analyses with APS and AVE as outcome. We presented two 
models for each outcome. In the first model, we adjusted for disease duration. In the second 
model, we adjusted for age, sex, and current smoking. We found associations between previous 
vascular events and EMPs expressing VCAM-1 (p=0.044 and p=0.047 for the two models, 
respectively). We also noted a non-significant trend between PMPs positive for CD40L and 
APS (p=0.06 and p=0.08).
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4.5 Paper V 
4.5.1 Association between smoking status and aPL positivity  
First, we compared ever vs. never smokers, and found that ever smokers were more prone to be 
positive for IgG aCL, IgG anti-β2GPI, and LA (data not shown). Ever smokers were then divided 
into former and current smokers.  
In a model adjusted for age, sex, and age at disease onset, former smoking was associated with  
IgG aCL, IgG anti-β2GPI, LA, and triple aPL positivity (see Table 8). 
 
Table 8: Association between current/former vs. never smoking and positive aPL (in 
comparison with negativity for the respective antibody), adjusted for age, sex, and age at 
disease onset, presented as odds ratio (95% CI)  
 IgG aCL IgM aCL  IgA aCL  IgG anti-β2GPI IgM anti-β2GPI IgA anti-β2GPI LA Triple positivity 
Age 1.01(0.99-1.04) 0.99(0.96-1.02) 0.99(0.97-1.82) 0.99(0.96-1.02) 0.98(0.95-1.02) 0.98(0.96-1.01) 1.0(0.97-1.02) 1.0(0.96-1.03) 
Age at SLE 
onset 
0.97(0.94-0.98)* 1.0(0.98-1.03) 1.0(0.98-1.04) 0.98(0.95-1.01) 1.01(0.98-1.05) 1.02(0.99-1.04) 1.0(0.97-1.05) 1.0(0.95-1.03) 
Sex (male) 0.7(0.2-1.6) 0.6(0.2-1.4) 0.7(0.3-1.7) 0.6(0.2-1.5) 0.5(0.07-1.7) 0.8(0.3-1.9) 1.2(0.5-2.5) 1.0(0.5-3.0) 
Current 
smoking 
1.3(0.5-2.9) 2.1(0.97-4.3) 2.0(0.9-4.1) 1.4(0.6-3.2) 2.2(0.9-5.5) 1.8(0.8-3.9) 2.1(0.9-4.5) 2.7(0.9-7.8) 
Former 
smoking 
3.0(1.6-5.8)* 1.1(0.5-2.2) 1.5(0.8-2.9) 3.1(1.6-6.1)* 0.6(0.2-1.7) 1.8(0.9-3.6) 3.1(1.6-5.9)* 4.0(1.7-10.0)* 
*p<0.05 in the multivariable model. aCL= Anticardiolipin,  anti-β2GPI= anti-β2 glycoprotein- I. LA=Lupus anticoagulant. 
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4.5.2 Associations between smoking, aPL and AVE  
Due to a lack of information on the temporal relationship between smoking and AVE and to 
increase the power, we used ever smoking in the main analyses of the association between 
smoking, aPL, and AVEs.  
In never smokers, aPL positivity was not associated with a history of AVE. In aPL-negative 
patients, ever smoking was moderately associated with arterial events but the combination of 
ever smoking and aPL was more strongly associated with both arterial and venous events. 
These associations were significant for  IgG/A aCL, IgG/A anti-β2GPI, LA, and triple positivity 
(data not shown). The additive interaction analysis showed a significant interaction between 
ever smoking and LA (attributable proportion due to interaction, AP=0.80, 95% CI 0.5 - 1.0) 
(see Figure 10), and ever smoking and triple positivity (AP=0.85, 95% CI 0.6 - 1.0) concerning 
the association with a history of AVE.  
 
Figure 10. Ever smoking and Lupus anticoagulant (LA) in relation to previous vascular 
events 
Art/ven = Any arterial/venous event. IHD=Ischemic heart disease. ICVD=Ischemic cerebrovascular disease. VTE= Venous thromboembolism. 
AP=Attributable proportion due to interaction
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5 SUMMARY AND DISCUSSION  
5.1 Our findings contribute to increased knowledge of aPL testing and improved 
APS diagnosis and clinical risk assessment 
5.1.1 Results from a new automated aPL assay had similar associations to clinical events as the 
routine ELISA 
In study I, we report only moderate agreement but similar associations with previous thrombotic events 
when comparing a new automated aPL method with standard assays in a large group of Swedish SLE 
patients. Overall, the associations with thrombosis were modest. This was also true for the associations 
with obstetric morbidity and thrombocytopenia investigated as complementary analyses.  
With this study, we were one of the first groups to conduct a comparative, clinical study between a 
new, fully automated aPL method and currently used routine ELISAs. Since the levels of performance 
were mostly comparable for the two assays, our results agree with the currently growing body of 
literature presenting more automated aPL assays as a promising strategy for facilitating aPL testing. 
These new assays may also improve reproducibility and reduce interlaboratory variation (98-105). If 
this is achieved, it would be a step forward in aPL diagnostics.  
5.1.2 aPL of IgG and IgM isotype show different associations with clinical events 
In study I, we noticed that IgG antibodies were primarily associated with VTE and ICVD while IHD was 
only associated with aPL of the IgM isotype. Our study thus gives some support to keeping both IgG and 
IgM aPL tests in the “standard investigation panel.” This is noteworthy since the rationale for keeping 
the IgM tests has been questioned as many (7, 23, 24, 33, 65, 74, 75, 82-84), though not all (36, 42, 76-
81), earlier studies have indicated poor clinical utility. Moreover, the information from our study is 
interesting since it indicates that isotype-specific patterns of APS manifestations may exist. These 
patterns should be further explored in prospective settings. 
5.1.3 Antibody titer is important when results from aPL testing are used for individual risk assessment  
From our results in study I, we conclude that associations with clinical events differ according to aPL 
titer. This is in accordance with previously well-established knowledge. Many earlier studies have 
reported that higher levels of aPL are more strongly associated with clinical events than lower levels (61-
68) and the current cut-offs for positivity were based on the best available evidence 2006 when the APS 
criteria were last modified (3). In our study, we examined how three different cut-offs performed in 
relation to previous thrombotic events. Surprisingly, we noticed that aPL titers below the criteria cut-off 
were also important, i.e. there were positive associations between such titers and clinical events. We 
have previously reported that low aPL titers are predictive of the first arterial event in a prospective study 
of SLE patients (30) and others have proposed that low titer aPL might be included in the diagnosis of 
obstetric APS (71). It is possible that different aPL cut-offs should be used for different clinical entities 
and situations, modified according to the purpose of aPL testing and background risk. This type of 
flexible approach could perhaps result in a more true estimate of the individual risk. 
5.1.4 LA and other factors such as smoking are also important when results from aPL testing are used 
for individual risk assessment  
The equivalent performance but modest agreement between the two assays in study I might appear 
paradoxical. An important reason for this inconsistency is probably that associations between thrombotic 
events and a single-positive aPL ELISA test are generally weak. These associations are clearly less 
strong than with LA positivity, which in our study performed better overall than both the specific aPL 
immunoassays. Similar observations have been published by other groups and have led to increased 
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awareness that the LA test is more powerful as a discriminator of clinical risk. There is also growing 
awareness of the importance of positivity in multiple tests (23, 24, 55). Triple positivity as defined by 
Pengo et al (90) includes the LA test. It is related to persistent aPL positivity and also to higher aPL titers 
(90, 248).  
Other vascular risk factors (30, 94) such as oral contraceptives and smoking are also important, however, 
and seem to interact with aPL and impact the overall risk for individual SLE patients (9). In study V, we 
report that despite the individual associations between smoking and aPL with AVE being rather modest, 
the combination of the two variables lead to a distinctive increase of the ORs.  A significant interaction 
was found between ever smoking and LA as well as aPL triple positivity for the association with AVE. 
These results are in line with the findings by Urbanus et al who reported that the combination of aPL and 
smoking was associated with a several-fold enhanced risk for the occurrence of MI and stroke in young 
women from the general population (9). We believe that this knowledge is important to account for in 
risk assessment of individual patients. In everyday practice, it implies that aPL-positive SLE patients who 
have never smoked are in a different risk category compared to aPL-positive former/current smokers. 
Based on this information, it would perhaps be wise to include smoking status in the APS risk scores that 
are currently being developed (91-93). 
In summary, we agree with Roubey (4) that aPL testing should in most situations be regarded as part of a 
general risk stratification for specific clinical events in certain groups of patients rather than a diagnostic 
procedure. A reliable risk estimate is crucial in the clinical situation since it is mandatory for planning 
surveillance and treatment of the individual patient. In this context, the risk for thrombosis or other APS 
manifestations must of course be compared to the risk of developing sideeffects from primary/secondary 
prophylaxis (18). 
 
5.2 Our findings contribute to the understanding of the pathogenesis of aPL-related 
disease and give clues to the search for new biomarkers 
5.2.1 Abnormal clot properties is a feature of APS  
In study II, we report for the first time that fibrin clots formed in vitro in plasma samples from APS 
patients have a decreased permeability compared to the clots formed in samples from healthy controls 
and from non-APS thrombosis controls. In addition, SEM images visually confirm denser fibrin structure 
in the samples from APS patients as compared to a control sample. Since tighter fibrin networks are 
more resistant to fibrinolysis (160-163) and impaired fibrinolytic capacity has been associated with APS 
(109, 184, 185, 187), we conducted additional turbidimetric lysis analyses. On a group level there was no 
clear difference in overall fibrinolysis function between the APS patients and the two control groups. 
However, fibrinolysis properties differed between APS subgroups. We observed that the APS patients 
with a history of arterial thrombosis had prolonged clot lysis time as compared to our two non-APS 
control groups.  
Our study adds APS to the growing list of conditions with increased cardiovascular and thrombotic risk 
where clots with abnormal architecture and decreased permeability are formed in in vitro assays (150-
159). This is interesting since the tendency to form tight fibrin networks in vitro could reflect an in vivo 
situation with disturbed fibrinolysis, due to for example decreased permeability of fibrinolytic factors 
through the clot (160-163), even though we could in study II only demonstrate hypofibrinolysis in the 
arterial subgroup of our patients. Moreover, efforts to explain our finding point to different factors of 
possible pathogenic importance. Under our experimental conditions, some factors known to contribute to 
fibrin gel porosity are kept constant (see section 1.5.3). Fibrin permeability thus depends mainly on the 
quantity and quality of sample fibrinogen but may also be affected by possible modulators in the 
investigated samples (166, 167). In agreement with previous studies (189), the APS patients in our study 
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indeed had high concentrations of fibrinogen. A high fibrinogen concentration is in itself a risk factor for 
CVD (176) and links between fibrinogen and activation/maintenance of autoimmune responses have 
been suggested (179). However, Ks values remained independently associated with group assignment 
after adjusting for fibrinogen, and fibrinogen hence does not seem to be the only factor of importance. 
Raised plasma levels of PAI-1, previously reported in patients with connective tissue disease (187), 
could play a role, given the known association between PAI-1 activity and fibrin permeability (150). 
APS patients have also been reported to have enhanced activity of FXIII, which correlates to both aPL, 
PAI, and fibrinogen (186) and which is probably relevant for clot structure and permeability (168). 
Altered levels of fibrinogen binding proteins could theoretically affect fibrin structure and so could 
cellular activity (168), possibly mediated by MPs. Previous studies demonstrate that MPs can bind to 
fibrin and affect its structure (170) (171). However, in our study, the numbers of different MPs in the 
investigated samples did not correlate with fibrin permeability. If abnormalities in circulating MPs are 
important for our current in vitro findings of atypical fibrin structure/function in APS, these MP 
abnormalities could be functional rather than quantitative in nature. However, if the primary aim of our 
study had been to explore the relationship between circulating MPs and fibrin permeability in APS, a 
modified version of the fibrin permeability assay would probably have been more suitable. In the assay 
we used for study II, large amounts of thrombin were added to initiate fibrin formation. Thus, the 
possible effect of TF, FXII, or even PS expression on MPs was bypassed, since thrombin is the common 
factor of the coagulation cascade (both extrinsic and intrinsic pathway). It is possible that if we had used 
a low dose of TF instead of thrombin as a reaction trigger, an approach probably better reflecting the in 
vivo processes (249) there would have been a correlation between numbers of MPs (which can for 
example express TF and expose PS, se discussion in section 5.2.2) and fibrin permeability.  
We detected a clear difference in fibrin permeability between patients and controls, but clinical subsets 
of APS patients could not (with a few exceptions) be separated. The latter finding was in some ways 
surprising given previous knowledge and literature in the field (171, 173-175), but our population size 
and design may not have been optimal for subgroup analyses. The main findings in our work regarding 
fibrin permeability and fibrin structure as visualised with SEM were verified in a study published by 
Celinska-Lowenhoff soon after ours (250). This study comprised a larger group of APS patients 
(n=126) none of whom were taking oral anticoagulants at the time of blood sampling and a control 
group (n=105) of patients frequency-matched for age, sex, current smoking, and type of prior 
thromboembolic event, in whom APS was excluded. Besides confirming our finding of increased 
fibrin permeability in APS, this study also demonstrated longer clot lysis times in the whole APS 
group compared to controls. The intergroup differences remained after adjusting for both fibrinogen 
and PA-I antigen. In a more recent publication, the same group reported an association between these 
clot properties and intima-media thickness in APS patients (251). Like us, Celinska-Lowenhoff et al 
reported that APS patients with arterial events had more pronounced clot abnormalities than other APS 
patients (250). Taken together, clot characteristics thus seem important for APS phenotype and 
prospective studies will reveal potential prognostic importance. Standardisation of the assay is critical 
in this context (252). Why the arterial subset displays more distinct clot abnormalities than the rest of 
the APS patients is not clear. Differences in levels or function of fibrinogen, fibrinolysis activators, 
and fibrinolysis inhibitors are possible explanations. The method we used to investigate fibrinolysis is 
known to be sensitive to concentration of PAI-I and fibrinogen (183) so group differences in these two 
variables, known to be associated with CVD risk in the general population (176, 178), are good 
candidates. Fibrinogen levels were indeed higher in the APS patients with arterial thrombosis 
compared to the APS patients without arterial events in our study (p=0.02), but PAI-I and other factors 
of possible importance were not measured. Larger groups of patients need to be investigated in order 
to construct multivariable models where all the variables of interest may be accounted for. 
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5.2.2 Increased number of MPs is a feature of APS and SLE but the exact relationship between MPs, 
aPL, and vascular events is unclear 
With study III, we were the first group to report that TF-expressing EMPs are much more frequent in 
samples from APS patients than in samples from healthy controls. We also demonstrated that total 
number of lactadherin-positive MPs, EMPs, and MMPs in APS patients were increased as compared to 
healthy controls, which is in agreement with most (199-202, 209) but not all (203) previous studies. 
However, the number of PMPs did not differ between APS patients and controls, a finding that is also 
supported by some previous studies (201, 203, 211) but in conflict with others (200). Recently, 
Chaturvedi et al published a study where they replicated our finding of increased number of total PS-
expressing MPs in APS as well as increased numbers of EMPs and TF-positive MPs compared to 
healthy controls. However, in contrast to our study, they reported an increase in PMPs but not MMPs 
(253). Our study also revealed that APS patients a had higher proportion of MPs negative to the PS 
marker lactadherin compared to healthy controls. Finally, the MP pattern did not discriminate between 
major clinical APS subsets such as “obstetric” and “thrombotic” APS. 
 
In study IV, a large study conducted to examine MPs in SLE patients and matched controls, we found a 
striking elevation of the total number of circulating MPs including platelet, endothelial, and leukocyte 
MPs in SLE patients. This is in agreement with some (204-206, 209, 214) but partially conflicting with 
other (207, 208, 210-212, 215) previous, smaller studies on similar clinical populations. Moreover, all 
investigations of MPs exposing inflammation and/or activation markers such as CD40L, TF, VCAM-1, 
HMGB1, and C4d also demonstrate clearly increased numbers in the SLE patients compared to the 
controls. These findings are, as far as we know, novel and they support and expand previous theories that 
ongoing cell activation, apoptosis and/or impaired clearance of cellular remnants is a general feature of 
SLE pathogenesis (254). Based on our findings in study III, our a priori hypothesis was that the MP 
profile could be used to distinguish SLE subgroups with APS and vascular events, but we found only 
borderline associations between such features and MPs. 
 
Some of the discrepancies between our findings and the findings in other MP studies in APS and SLE 
may be explained by methodological differences as there are many such factors that could influence the 
results (255). These factors are associated with different steps of the pre-analytical handling, 
centrifugation protocol, and the specific method used for MP detection. 
 
Overall, the data from study III and IV support or give rise to several hypotheses about the pathogenesis 
of aPL-related disease: APS and SLE. 
 
One hypothesis on the role of MPs in APS pathogenesis, presented in a review by Pericleous et al (198), 
suggests, based on several separate studies (199, 201, 202),  that aPL positivity is sufficient to stimulate 
production of elevated EMPs. However, the properties of these EMPs could be different in patients with 
clinical APS compared to carriers of nonpathogenic aPL since it has been shown that only plasma from 
the former group can stimulate production of procoagulant EMPs (199) and that PMPs are not raised in 
aPL-positive subjects unless they had a previous thrombosis (201). Partly consistent with this hypothesis, 
the result from study III could imply that aPL positivity in itself is enough to cause chronic endothelial 
and monocyte activation associated with increased EMP  and MMP count, but additional factors are 
required for platelet activation, PMP release, and APS events to subsequently occur. The aPL-positive 
patients in our study had more circulating EMPs and MMPs as compared to healthy controls. The fact 
that PMP count did not differ from controls might be due to the fact the samples were not obtained at the 
time of a clinical event but at a point in time when the patients’ disease was well-treated, i.e associated 
with lower risk of new events.The MP abnormalities that we detected in the APS samples indicate 
nevertheless that the total surface covered with negatively charged PS is increased and exposed to the 
coagulation system also when APS patients are in a tranquil phase of their disease. This observation is 
consistent with the presence of a chronic pro-coagulant state. Additional triggers, as described by the 
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second hit hypothesis of APS pathogenesis (19, 54), may in this setting more easily initiate clinical 
events. The increased number of TF-exposing EMPs is particularly interesting. TF is pivotal for 
coagulation initiation, TF has previously been proposed to play a role in APS pathogenesis through aPL-
mediated upregulation on different target cells (54), and TF activity from MPs of undetermined cellular 
origin is increased in APS patients compared to aPL carriers (217). However, to better assess the 
relevance of our findings, it would be of pivotal interest to measure the pro-coagulant activity of TF 
expressed on the EMPs. TF in the circulation may occur in different truncated forms, including an 
“active” and a “non-active” form (256). Various factors have been proposed to regulate TF activity such 
as the characteristics of the PS-positive surfaces (activated cells or MPs) where the coagulation reactions 
occur, factor VIIa binding, and tissue factor pathway inhibitor (257, 258). These variables could 
influence the extent to which the increase of TF-expressing EMPs that we detected confers a true 
increase in TF activity in APS patients.  
Contrary to our findings in APS patients, we found increased levels of PMPs in SLE patients. PMPs 
exposing CD40L were also higher than in matched controls. These MPs probably contribute to 
autoantibody production and disease pathogenesis. Platelets and platelet activation are known to be 
important in SLE (259). CD40L was originally described on different immune cells, but more recent 
studies have revealed that platelets are in fact the main source of this inflammatory mediator, 
producing more than 90% of soluble CD40L (sCD40L). Platelet-derived sCD40L acts as a trigger for 
endothelial activation and inflammation, for example through increasing expression of VCAM-1. 
Levels of CD40L on immune cells as well as soluble sCD40L are increased in SLE, and a link to 
disease activity and B-cell activation has been demonstrated (260-263). Platelets from SLE patients 
can activate mesangial cells through CD40/CD40L interactions leading to glomerular injury associated 
with nephritis (264). There are also indications that platelet CD40L contributes to activation of the 
type I IFN system in SLE (265). PMPs may act as a vector for CD40L (CD154) signalling by 
removing CD40L from the site of platelet activation and thereby making it possible for CD40L to 
encounter and activate its receptor on target cells. If the target cells are B-cells, this can ultimately lead 
to production of an antigen-specific response (266).  
 
The increased levels of MPs expressing the complement degradation product C4d in SLE patients is 
consistent with previous findings of increased levels of platelet-bound C4d in SLE. Platelet-bound C4d 
has in fact been proposed as a useful lupus biomarker, associated with all-cause mortality, vascular 
events, and aPL (267-272). Contrary to our expectations, we did not, however, find an association 
between C4d-exposing MPs and vascular events or aPL/APS. It is important to note that measurement 
of C4d on MPs was performed in the absence of lactadherin, as they both are conjugated with the same 
dye (FITC). Thus, C4d was measured on “all” MPs regardless of whether they exposed PS or not. By 
not initially differentiating MPs by PS expression, we found ten times more C4d+ PMPs and five times 
more C4d+ EMPs in patients than controls.  
 
The high number of EMPs as well as EMPs positive for the adhesion molecule VCAM-1, and 
coagulation initiator TF in the SLE samples indicate a general endothelial dysfunction and activation 
similar to what we hypothesised for APS in the paragraph above.  
VCAM-1 is reported to have a regulatory role in peripheral tissue inflammation in several diseases 
such as infections, chronic inflammatory conditions, and cardiovascular diseases (273). Previous SLE 
studies have shown increased soluble (s) VCAM-1 levels in patients compared to controls (274, 275) 
and we reported previously that sVCAM-1 levels were predictive of cardiovascular events and of 
cardiovascular mortality (30, 231). However, study IV is the first to demonstrate an increased number 
of MPs expressing VCAM-1 in SLE. Surprisingly, we found only borderline association with VCAM 
1-positive MPs and vascular events in this population. 
Apart from a study by Nojima et al, where increased TF expression on monocytes was found to be 
associated with thrombosis and aPL in SLE patients (276), little is known about the role of TF in SLE. 
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Study IV is the first to investigate numbers of TF-expressing MPs in a large group of SLE patients. 
Despite the important role that TF-positive MPs seem to play in vascular disease (277), including APS 
as reported in study III, and their ability to increase thrombin formation in vitro previously 
demonstrated by us (278), we did not find any association between these MPs and vascular 
events/secondary APS in SLE. This is not easy to explain. There seem to be factors in SLE that lead to 
signs of endothelial activation/dysfunction even in the absence of aPL and overt vascular disease. 
Whether they are the same or different from the factors causing endothelial activation/dysfunction in 
primary APS, a condition emerging as a systemic autoimmune disease with close links to SLE rather 
than a simple autoimmune coagulopathy (218), remains to be elucidated. As discussed previously, it is 
however important to remember that the level of activity of the TF expressed by the MPs was not 
measured in our studies. This could in fact be the variable that differentiates SLE patients with 
vascular phenotype from the rest of the SLE population. 
 
The increased number of MMPs exposing HMGB1 found in our SLE patients could constitute a source 
of extracellular HMGB1 with potential to trigger autoantibodies. HMGB1 is an intranuclear protein that 
under normal physiological circumstances binds to DNA and helps to control gene transcription. When it 
is translocated to the extracellular space during for example apoptosis, HMGB1 can stimulate pathogenic 
mechanisms in inflammatory and autoimmune diseases.!High titers of anti-HMGB1 autoantibodies as 
well as increased levels of circulating HMGB1 have been detected in SLE patients (279). Levels of 
HMGB1 are related to disease activity (280). Moreover, the ability of HMGB1 to form stable complexes 
with other nuclear components from apoptotic cells is probably crucial for the loss of tolerance to auto-
antigens and inflammatory response in SLE. However, HMGB1 can, like TF, undergo post-translational 
modifications that alter its activity (279). Our flow cytometric results demonstrate high expression of 
HMGB1, but we cannot assess its functional activity.  
Alternative hypothesis about mechanisms in aPL-related diseases can be generated by our finding that 
APS patients had a large proportion of MPs negative for the PS exposure marker lactadherin.To our 
knowledge, this is a new finding in APS, but a recent Danish study report similar results in SLE patients. 
In this study, the patient samples contained increased numbers of MPs negative to the PS exposure 
marker annexin V, and it was suggested that this could have implications for phagocyte recognition 
(208). As pointed out by the Danish group, it is possible that this is caused by true lack of surface PS 
exposure or enzymatic degradation of PS. Blockage by endogenous ligands/immunoglobulins is another 
plausible explanation (208). β2GPI or β2GPI/anti-β2GPI complexes could possibly block a significant 
amount of the PS on MPs in patients with aPL-associated disease. Both antiβ2GPI antibodies and the 
circulating levels of their antigen β2GPI are increased in APS patients compared to controls (116) and it 
has been demonstrated that β2GPI binds to PS-expressing PMPs (112). In SLE, increased MP content of 
both β2GPI (216) and IgG (281) as compared to MPs from controls has been reported. Hypothetically, a 
substantial amount of the lactadherin-negative MPs we detected in our APS patients could be PMPs 
where PS was blocked by β2GPI/antiβ2GPI. With a different method for MP detection, not dependent on 
PS for MP definition, an increase of PMPs in APS would perhaps have been detected. Such an increase 
could, at least partly, be caused by antiβ2GPI interfering with β2GPI-mediated phagocytic clearance and 
contribute to the pro-coagulant state of APS (112). In APS, several factors such as smoking and 
infections may lead to increased release of circulating MPs and to increased oxidative stress (244, 282).  
β2GPI is upregulated by oxidative stress (283). One could speculate that the upregulation of the this 
“vacuum cleaner” (108) constitutes a sort of feedback mechanisms to mediate increased clearance in 
certain situations, but if anti-β2GPI levels also become augmented, phagocytosis is inhibited and levels 
of MPs with pro-coagulant potential remain elevated. Strategies to test the above hypothesis of APS-
associated PMP increase masked by β2GPI/anti-β2GPI binding could be to examine the share of 
β2GPI/anti-β2GPI-positive MPs or to examine numbers of “PS-negative” MPs positive for platelet 
surface markers. Recently, an excess of serum lactadherin was reported in SLE-patients and suggested to 
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be associated with decreased phagocytic clearance and disease activity (284). Hence, this molecule could 
affect our analyses and disease pathogenesis in a way similar to what was described for β2GPI/anti-
β2GPI above. 
Indeed, the high number of lactadherin-negative MPs in our APS study and the striking rise of C4d-
positive lactadherin-negative MPs in our SLE study as well as the results of the Danish SLE study (208) 
make it reasonable to believe that measuring MPs regardless of PS exposure is important in both APS 
and SLE. The “classical” way of defining MPs (i.e. size and PS expression) may not be suitable for such 
patient groups. Hypothetically, clinical subsets like SLE patients with vascular events and aPL as well as 
“obstetric” and “thrombotic” APS patients may be more clearly distinguished by MP profile if “all” MPs 
( i.e. also PS-negative MPs), were measured and further phenotyped. New associations with other 
parameters such as serological profile and fibrin permeability may emerge with such an approach as 
well.  
Despite the methodological concerns that remain, we would like to underline that with our current 
laboratory method for MP detection, we have addressed many of the analytical and pre-analytical 
concerns associated with MP flow cytometry (213, 255). We used a flow cytometer with relatively good 
sensitivity for detection of MPs (245), lactadherin which is a more sensitive marker than annexin V for 
PS exposure (196), and phalloidin as a “sample quality control” to identify cell fragmentation which 
could occur as a consequence of freezing/thawing or other types of pre-analytic handling (245). 
Finally, when discussing MPs as biomarkers for APS and SLE, it is of course important to recognise the 
need for prospective studies. It is possible that our future follow-up of these patients will provide us with 
insights on how MP profile (analysed with our current method or a modified approach) could be used as 
predictor of clinical outcome. 
  
5.2.3 Smoking is important for aPL positivity and aPL-related thrombosis 
In study V, we report an association between cigarette smoking (ever smoking and in particular former 
smoking) and aPL positivity in SLE patients. Moreover, an interaction between ever smoking and aPL 
was noted for the association with previous vascular events. 
Our results are interesting since previous experimental studies indicate that smoking plays a role in the 
pathogenesis of aPL-related disease. Smoking is associated with increased oxidative stress which can 
affect a number of factors of importance for the development of aPL-associated events (54, 285) such as 
the endothelial surface receptors (132) and the conformation of the β2GPI- molecule. Patients with APS 
have a larger proportion of oxidized β2GPI than controls (116) which probably has implications for 
antibody binding (120). Smoking is also associated with increased levels of circulating MPs, which (as 
discussed in section 5.2.2) is another factor through which smoking could mediate increased thrombotic 
risk. Theoretically, there are thus a number of plausible mechanisms through which smoking in 
combination with other environmental and/or genetic factors could lead to immunological and vascular 
changes that are critical for clinical APS manifestations to occur.  
It is intriguing that it is mainly former and not current smoking that is associated with aPL positivity in 
our study. This association was primary found for the antibodies of IgG isotype and for LA positivity. 
Hypothetically, smoking discontinuation could change the immunological balance and trigger either an 
aPL “class switch” from IgM to IgG or a rebound IgG production, as proposed by Rubin et al. In their 
study, autoimmune-prone mice exposed to smoke displayed a lower spontaneous production of IgG auto-
antibodies than control mice, but after smoking was discontinued, IgG autoantibody production was 
augmented. They supported their findings in the murine model by investigating SLE patients and 
reported that, compared to non-smokers, patients who smoked at the time of diagnosis had lower levels of 
IgG anti-dsDNA while former smokers had higher levels (286). Even though larger clinical studies in 
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SLE patients, including our own, have reported partly conflicting results regarding the association 
between anti-dsDNA and former smoking (287, 288) the hypothesis put forward in the paper by Rubin et 
al is interesting. Through this mechanism or other pathways, smoking may cause a rise in IgG 
autoantibodies such as aPL of such magnitude that it could constitute a “triggering event” in individuals 
that are previously positive for aPL in lower titers.  
 
5.4 Limitations 
The five studies conducted are cross-sectional with the inherent limitations related to such a study design; 
they can generate hypotheses about associations between variables but not establish temporal and/or 
causal relationship. In the case of APS, it is known that aPL titers can decrease or increase over time, for 
example due to infections (289). This is important to bear in mind when judging the “snapshot” that these 
cross-sectional studies provide of the association between aPL and other variables like clinical APS 
manifestations. Moreover, since aPL positivity is predictive of cardiovascular mortality (231), there is a 
risk for selective survival bias. In other words, there is a risk that some aPL-positive patients die before 
study entry and are thus not included in our analyses. It is also important to mention that in study V there 
is, due to the study design, a risk that reverse causation explains our main finding regarding the 
association between former smoking and aPL. 
It is difficult to determine how relevant our findings of abnormal fibrin clot properties, fibrinolytic 
function, and MP profile are for the in vivo situation in APS and SLE patients. Regarding MPs, we have 
found striking differences in the number of MPs between patients and controls but we have not 
investigated the activity of the proteins they express or their overall effect on biological processes. 
Moreover, further method development and standardisation may be needed, as discussed in 5.2.2. 
Concerning the in vitro methods we used to study fibrin network characteristics and fibrinolysis, one 
must keep in mind that these methods test only some of the factors that could be important for the 
situation in vivo. Factors of possible in vivo relevance but not fully taken into account by our methods 
include cell activity, thrombin generation and local blood flow (168). 
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6 CONCLUSIONS 
• Antiphospholipid determinations by a new automated assay show associations to previous 
thrombotic events similar to the routine ELISA. 
• Lupus anticoagulant positivity, antiphospholipid titer, and isotype are, together with smoking 
status, important for vascular risk assessment in patients with systemic lupus erythematosus. 
• Lupus anticoagulant  is a more powerful marker of thrombotic history than anticardiolipin and 
anti-β2 glycoprotein I.  
• Abnormal fibrin clot properties, fibrinolytic function, microparticle profile, and smoking may 
contribute to the pathogenesis of antiphospholipid-associated disease. 
• Microparticles are more abundant in patients with antiphospholipid syndrome and in patients 
with systemic lupus erythematosus than in controls.  
• The exact relationship between antiphospholipid antibodies, vascular events, and microparticles 
in patients with systemic lupus erythematosus have to be further studied and we believe that it is 
important to examine phosphatidylserine -negative microparticles more closely. 
• The findings in this thesis merits further prospective and mechanistic investigation to evaluate 
their importance for the development of new biomarkers for antiphospholipid-related disease . 
  
 
 
 
Fig 11: A summary of factors relevant to pathogenesis and diagnosis of aPL-associated disease 
studied in this thesis  
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